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ABSTRACT 
Asthma is a high-stress, chronic medical condition; 1 in 12 adults in the United 
States combat the bronchoconstriction from asthma.  However, there are very few strong 
studies indicating any alternative therapy for asthmatics, particularly following a cold 
incidence. Vitamin C has been proven to be effective for other high-stress populations, 
but the asthmatic population has not yet been trialed.  This study examined the 
effectiveness of vitamin C supplementation during the cold season on cold incidence and 
asthmatic symptoms.  Asthmatics, otherwise-healthy, who were non-smokers and non-
athletes between the ages of 18 and 55 with low plasma vitamin C concentrations were 
separated by anthropometrics and vitamin C status into two groups: either vitamin C (500 
mg vitamin C capsule consumed twice per day) or control (placebo capsule consumed 
twice per day).  Subjects were instructed to complete the Wisconsin Upper Respiratory 
Symptom Survey-21 and a short asthma symptoms questionnaire daily along with a 
shortened vitamin C Food Frequency Questionnaire and physical activity questionnaire 
weekly for eight weeks.  Blood samples were drawn at Week 0 (baseline), Week 4, and 
Week 8.  Compliance was monitored through a calendar check sheet.  The vitamin C 
levels of both groups increased from Week 0 to Week 4, but decreased in the vitamin C 
group at Week 8.  The vitamin C group had a 19% decrease in plasma histamine while 
the control group had a 53% increase in plasma histamine at the end of the trial, but this 
was not statistically significant (p>0.05).  Total symptoms recorded from WURSS-21 
were 129.3±120.7 for the vitamin C and 271.0±293.9, but the difference was not 
statistically significant (p=0.724).  Total asthma symptoms also slightly varied between 
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the groups, but again was not statistically significant (p=0.154).  These results were 
hindered by the low number of subjects recruited.  Continued research in this study 
approach is necessary to definitively reject or accept the potential role of vitamin C in 
asthma and cold care. 
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CHAPTER 1: INTRODUCTION 
Overview 
 Asthma impacts 1 in 12 individuals in the United States (Akinbami, 2012).  
Although this disease affects a huge population, little research has been done to examine 
a natural remedy for its debilitating symptoms.  Complementary and alternative care 
methods are needed since the traditional medications are expensive and possess potential 
side effects.  Asthmatics are also more prone to experience a common cold every year 
than individuals without asthma.  Vitamin C supplementation has been proven effective 
in normal, healthy populations to prevent colds (Pauling, 1971).  This effectiveness of 
vitamin C for preventing colds is increased in populations experiencing high stress 
conditions, such as athletes and military personnel (Jacob, 2002).  Although vastly 
different physiologically, asthmatics are subject to high stress during asthma attacks, 
when their body is unable to control the reactive oxygen species (ROS) and inflammation 
caused by leukotrienes and histamine (Liu, 2013).  Due to vitamin C’s role as an 
antioxidant, its role as a possible Complementary and Alternative Medicine (CAM) 
therapy is still untapped in the asthmatic population.   
 The relationship between vitamin C and colds has been tested for many decades 
(Akinbami, 2012), and the most effective outcomes of vitamin C supplementation are for 
high stress subjects (Jacob, 2002).  However, in the general population, the benefits of 
high dose vitamin C on combating the common cold are mixed.  We recently completed a 
study in Spring 2011 in male non-smokers at Arizona State University.  Comparing 15 
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subjects in treatment and 13 subjects in control, there was a significant difference in 
plasma vitamin C and cold symptoms between the two groups (Johnston, 2014).   
 On the other hand, current studies examining the effect of vitamin C in the 
asthmatic populations have limited results.  Studies have not shown significant effect of 
vitamin C on decreasing cold symptoms in asthmatic populations.  However, no adverse 
effects have been documented (Milan, 2013).  One randomized controlled trial examining 
leukocyte vitamin C level in asthmatics after one month supplementation showed a 
significant difference in leukocyte vitamin C levels in the treatment group compared to 
the controlled group (Nadi, 2012).  As indicated by the latest Cochrane review, more 
research is necessary to confirm the usefulness of vitamin C as a complementary therapy 
in asthmatics (Milan, 2013).  
The study at hand attempted to bridge the two areas of research.  This study 
examined the effect of vitamin C supplementation for preventing colds in asthmatics and 
for decreasing asthma symptoms  over an 8-week session.  The study took place at the 
height of cold and flu season in January through April 2014.  To thoroughly examine the 
effects, a placebo group was compared to the study group (1000 mg vitamin C daily).  
Through randomization, this double-blind study attempted to provide a missing link in 
asthma and vitamin C research.  This study was the first of its kind to examine whether 
vitamin C supplementation reduces the incidence and severity of colds in an adult 
asthmatic population. 
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The Study Purpose 
 The objective of this study is to examine the effect of vitamin C supplementation 
(1000mg/day) for decreasing cold symptoms in asthmatic adults through a validated cold 
and respiratory symptom questionnaire administered daily over an 8-week period.  To 
determine participation consistency, self-reported ingestion of capsules is indicated 
through a calendar submitted at the last blood draw (Week 8).  Subjects were advised to 
consume the pill with meals and record consumption on a provided, simple weekly 
calendar. 
Hypotheses 
H1: 8 weeks of 1000 mg daily vitamin C supplementation will decrease the incidence of 
colds and/or cold symptoms in adults with asthma. 
H2: 8 weeks of 1000 mg daily vitamin C supplementation will decrease asthma 
symptoms and blood histamine concentrations in adults with asthma.  
Definition of Terms 
Asthmatic adults: Participant over the age of 18 who has been diagnosed by a Medical 
Doctor sometime in their lifespan with asthma. 
BMI: A ratio of weight to height.  Calculated as weight (in pounds) / height
2
 (in
2
) x 703. 
Common cold: An infectious disease of the upper respiratory system that includes 
symptoms of stuffy/runny rose, persistent cough, weakness, fatigue, and sore throat. 
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Excessive exercise: An exercise regimen to train a person for a high-intensity activity, 
such as a marathon.  This schedule typically entails multiple hours of daily exercise. 
Gluten intolerance: A condition where a person experiences discomfort when ingesting 
gluten. 
Histamine: A common blood marker used to indicate inflammatory status in the body 
Low vitamin C status: A plasma vitamin C level ≤ 0.75 mg/dL. 
Smoker: Someone who consistently uses ≥10 cigarettes per week. 
Vegan: A person who avoids any foods related to or coming from any animal. 
Delimitations 
 Applicable subjects include individuals ages 18 to 55.  Subjects must have been 
previously diagnosed with asthma by a Medical Doctor.  Smokers will be excluded from 
the study, due to the increasing inflammatory conditions associated with smoking and 
increasing cold or asthma symptoms (Omenaas, 2003).  Participants with normal to low 
plasma vitamin C status will be included.  Finally, interested candidates who already take 
supplements containing vitamin C will be excluded.  Generalizability will also be limited 
by the small sample size.  The study will last from January 2014 to April 2014. 
Limitations 
 Limitations include self-reporting ingestion of capsules, symptoms relating to 
cold and asthma for the Wisconsin Questionnaire, and diagnosis by an MD.  Also, 
observation of cold symptoms only lasts for the specific 8 weeks in the study.  Thus, the 
possibility for missing any cold or symptom events outside the time block exists.  
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CHAPTER 2: LITERATURE REVIEW 
Review of Vitamin C 
History.  As with most micronutrients, the history of vitamin C is tightly 
intertwined with its deficiency disease: scurvy (Gropper, 2013).  Once humans began to 
explore the world by sea around the sixteenth century, sailors, particularly British sailors, 
fell ill to this disease.   It was not until the 20
th
 century that vitamin C was isolated and 
defined by its structure (Gropper, 2013).  Even though present-day societies understand 
the role of vitamin C in scurvy, the disease still exists today.  However, the impact of 
scurvy is significantly less than it was in the sea-faring days.  Rather, scientists currently 
focus on the potential effect of vitamin C on various illnesses and conditions; one in 
particular is health prevention by its antioxidant roles. 
Scurvy has been around much longer than the sailors.  One of the earliest cases of 
scurvy was found in the skeletal remains of a child in England.  Archeologists found 
lesions in the endocranial and ectocranial sections of the skull.  The skeleton is 
considered to be as old as 2200-1970 BC (Mays, 2008).  A more abundant record of 
scurvy starts with the Spanish and Portuguese explorers.  One of the lead explorers, 
Vasco da Gama, observed swollen extremities and gums with a lack of appetite among 
his crew members.  These symptoms went away after trading for oranges from Moorish 
traders.  A few months later on their return journey, the symptoms returned and 30 men 
died from the illness.  Yet, da Gama associated the illness with displeasure of the gods, 
rather than from the citrus (Carpenter, 1986; Baron, 2009).   
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In the sixteenth century, British sailors recorded their experience with scurvy.  Sir 
Richard Hawkins, an English sea captain, claims he saw at least 10,000 men develop the 
deadly symptoms of scurvy in his 20 years of sailing (Carpenter, 1986).  Sir Hawkins 
eventually began trading for citrus on his journeys to prevent the scorbutic issues (Baron, 
2009).  In 1590, Sir Hawkins bought hundreds of lemons and oranges from Brazil just to 
prevent scurvy in his men.  From speculation, Sir Hawkins had experience with scurvy 
from being a prisoner of war in Spain prior to his sailing expeditions.  He wrote, “that 
which I have seene more fruitful is sower oranges and lemons…I wish that some learned 
man would write of it, for it is the plague of the sea,” (Baron, 2009).  A primary reason 
for this high incidence of scurvy among his men was due to the fact that only a surgeon 
was on board.  Physicians who would write and investigate diseases did not contact many 
people with scurvy, since it mostly happened while at sea (Carpenter, 1986).  One of the 
first research trials related to scurvy involved James Lancaster in 1601.  He gave each of 
his sailors on one of the British three spoonfuls of lemon juice each morning while three 
other ships did not have lemon juice.  Interestingly, there were little differences in the 
mortality rates of all four ships; however Lancaster still considered his methodology a 
success (Baron, 2009).   
Major writings of vitamin C preventing and treating scurvy happened in the 17
th
 
century.  A surgeon on the HMS Salisbury, James Lind, was one of the first few people to 
complete a case-controlled study regarding scurvy (Baron 2009; Bartholomew, 1753). On 
May 20, 1747, he selected 12 individuals with a similar degree of severity with scurvy, 
placed them in the same quarters, and fed them similar diets.  He split them into pairs, 
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with each pair receiving one of the following treatments: cider, elixir of vitriol, vinegar, 
sea water, purgative electuary, or two oranges with one lemon.  The only pair of scorbutic 
sailors to heal was the last pair fed the citrus (Baron 2009; Bartholomew, 1753).  Even 
with this proof, most people were hesitant to accept citrus as a treatment due to the 
stubbornness of scholars and their traditional mannerisms (Carpenter, 1986).  
Although Lind associated the cure for scurvy with citrus fruits in early 17
th
 
century, it was not until the early 20
th
 century when vitamin C was officially discovered.  
In 1907, Axel Horst and Alfred Frohlich utilized their research in Guinea pigs to indicate 
a single, specific anti-scurvy component.  However, these two researchers did not isolate 
the single component.  Rather, a Hungarian biochemist named Albert Szent-Gyorgyi 
identified the structure of vitamin C as well as vitamin P.  He worked with Charles G. 
King, a researcher at the University of Pittsburgh, and published their findings of the 
isolated vitamin C in April 1932 (Grzybowski, 2013).  Perhaps the largest obstacle in the 
isolation of vitamin C was the amount of samples; Szent-Gyorgyi used Guinea pigs and 
bovine renal tissue during his studies.  He soon discovered he could find vitamin C from 
the Hungarian pepper, which was far more abundant in the city he researched in, Szeged 
(Grzybowski, 2013).  One of the scientists working with Szent-Gyorgyi, Norman 
Haworth, gave vitamin C the name “ascorbic acid”, which means “without scurvy” in 
Latin (Grzybowski, 2013).  Szent-Gyorgyi’s work with vitamin C allowed him to win a 
Nobel Prize in physiology and medicine (Gropper, 2013; Grzybowski, 2013).  
Today, most research revolves around the antioxidant function of vitamin C in the 
body.  This antioxidant function theoretically supports actions to prevent and perhaps 
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cure common chronic illnesses.  By essentially satiating the electron needs of reactive 
oxygen species (ROS), vitamin C prevents damage to DNA in the cells, thus preventing 
chronic diseases and hindering their progression in the body (Yu, 2013).  One particular 
focus is its use in preventing the common cold.  Although limited groups have shown 
statistically significant benefits of vitamin C in this regard, in the general population 
Vitamin C supplementation has little success. Yet, vitamin C is still one of the first 
sought remedies during cold and flu season (Hemila, 2013).  More detail about the role of 
vitamin C in diseases will be discussed in later sections of this review. 
Biochemistry. Vitamin C, also called L-ascorbic acid or ascorbate, is one of the 
essential water-soluble vitamins in the human diet.  In fact, some researchers go as far as 
to say that vitamin C is “the most important water-soluble antioxidant in human plasma,” 
(Liang, 2001).  Ascorbate is a 6-carbon α-ketolacetone with two freely donateable 
hydrogens from the two hydroxyl carbons (Gropper, 2013; Rose, 1993).  Vitamin C is 
typically found in one of two forms: ascorbic acid (reduced form) or dehydroascorbic 
acid (the oxidized form after donation of hydrogens).  Semidehydroascorbic acid is 
considered to be the intermediate, as the mono-oxidized form.  However, this form is 
mostly found in the body in the interconversion of ascorbic acid to dehydroascorbic acid, 
DHA (Gropper, 2013; Rose, 1993).  Although existing in both L- and D-isomers, the L-
isomer of ascorbic acid is the biologically active form in humans (Rose, 1993).   
 In humans, ascorbic acid does not need any kind of alteration in order to be 
absorbed from the lumen of the small intestine (Gropper, 2013).  In the small intestine, 
ascorbic acid transports into the brush border cells with the assistance of sodium-
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dependent vitamin C transports 1 and 2 (SVCT 1 and 2), also called sodium-ascorbate co-
transporters (Savini, 2008).  SVCT 1 and 2 show specific affinity for the L-ascorbic acid.  
A Na
+
/K
+
-ATPase provides optimal energy for the ascorbic acid to cross the 
electrochemical barrier (Savini, 2008).  However, ascorbic acid is not the only form of 
vitamin C that can be absorbed.  Dehydroascorbic acid (DHA) is also absorbed from the 
small bowel.  Through the use of glucose transporters (GLUTs) 1, 3, and 4, DHA is able 
to cross through the intestinal cells.  This is accomplished because of the similarities of 
DHA with glucose.  However, this also poses a problem.  Often, these transporters can be 
saturated with glucose, providing a competition for DHA (Liang, 2001).  This is 
particularly apparent as glucose in the human diet is over one thousand times more 
evident than vitamin C, considering humans consume glucose in grams versus the 
milligrams of vitamin C contained in human foods.  In the cell, DHA is quickly reduced 
to ascorbic acid by the oxidation of glutathione (Gropper, 2013).  In fact, ascorbic acid 
accounts for 95% of vitamin C in human plasma (Liang, 2001).  If DHA is too high in the 
body, it would act as a pseudo-ROS, causing the very problem ascorbic acid works to 
prevent. 
Ascorbic acid and DHA generally flow in the blood unbound (Wilson, 2005).  
The body tightly regulates vitamin C concentration (Padayatty, 2004).  However, most 
adults are considered to be deficient, yet not scorbutic.  Some researchers use the 
following scale to interpret serum vitamin C levels: <11 µmol/L is considered to be 
deficient, 11-28 µmol/L is inadequate, and >28 µmol/L is adequate (Lam, 2013).  Other 
studies have found that a plasma vitamin C concentration ≥ 50 µmol/L is reflective of 
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decreased risk of damage from free radicals (Krajcovicova-Kudlackova, 2007). The 
adrenal and pituitary glands have the highest amounts of ascorbic acid, yet vitamin C can 
also be found in liver, heart, brain, white blood cells and muscle (Gropper, 2013; Wilson, 
2005; Hornig, 1975).  Similarly to cells in the small intestine, absorption of ascorbic acid 
into cells in the rest of the body occurs by SVCT 1 and, primarily, SVCT 2 while DHA 
competes with glucose for its absorption through GLUT 1, 3, and 4 (Wilson, 2005).   
Vitamin C is considered to be generally non-toxic although it has a tolerable 
Upper Limit.  Excess ascorbic acid is usually excreted in the urine.  Part of this 
“nontoxic” association is due to the bioavailability of ascorbic acid.  Doses of vitamin C 
up to 200mg resulted in 100% absorption in the general population; however intakes 
above 200mg resulted in decreased absorption from the intestinal lumen (Deruelle, 2008).  
Patients with abnormal iron metabolism or kidney stones may experience dangerous side 
effects as intake increases, particularly through the use of supplements (Gropper, 2013; 
Deruelle, 2008).   
Sources, recommended intake: natural and supplemental.  Arguably, the best 
natural sources of vitamin C are fresh colorful fruits, vegetables, and juices.  Common 
sources are included in Table 1. 
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Table 1.  
Common Sources of Vitamin C (Gropper 2013; Levine, 1999). 
Food Amount of vitamin C 
Strawberries, sliced, 1 cup 90-95 mg 
Orange, 1 medium 80 mg 
Red pepper, raw, ½ cup 65 mg 
Kale, cooked, 1 cup 55 mg 
Kiwi, 1 medium 75 mg 
Orange Juice 50-90 mg 
 
Vitamin C is considered to be a very labile chemical (Levine, 1999).  Cooking, 
freezing, and exposure to air cause a decline in ascorbic acid in foods.  Even the 
purchaser source of vegetables and fruits can cause differentiation in amounts of ascorbic 
acid.  For instance, broccoli purchased from a larger company-owned market such as 
Fry’s or Safeway will have 33% less vitamin C than from the independent grower 
(Levine, 1999).  Additionally, cooking can have a variety of effects.  One study found a 
20% decrease in plasma vitamin C from subjects who ate cooked broccoli compared to 
those who consumed fresh broccoli (Deruelle, 2008).  Another study found that boiling 
can decrease 50-80% of available ascorbic acid in vegetables (Levine, 1999).  Finally, 
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orange juice, arguably the most popular source of vitamin C in society, can have vastly 
differing amounts of vitamin C levels.  In terms of long term storage, it has been found 
that freezing orange juice and thawing prior to consumption is the optimal way to utilize 
orange juice as a source of vitamin C (Johnston, 2002).  
The Recommended Dietary Allowance for vitamin C is 75 mg for females and 90 
mg for men (Monsen, 2000).  The RDA for vitamin C was originally established to 
prevent scurvy (Omenaas, 2003).  However, those with increased states of inflammation 
are recommended to consume more daily.  Some individuals who may have increased 
needs of vitamin C are smokers, pregnant women, and athletes (Gropper, 2013; Monsen, 
2000; Omenaas, 2003).  In fact, research has established that smokers should consume an 
additional 35 mg of vitamin C compared to their nonsmoking counterparts (Gropper, 
2013).  Some individuals should moderate their intake of vitamin C just below the RDA.  
These groups include those who metabolize oxalate into kidney stones and those who 
have impaired iron metabolism; vitamin C can increase iron absorption, which could be 
deleterious for those with hemochromatosis, or excessive iron in the body (Deruelle, 
2008; Massey, 2005). 
The requirement of exogenous vitamin C is due to the fact that humans are one of 
the few mammals that cannot produce vitamin C from glucose.  Homo sapiens lack the L-
gulonolactone oxidase enzyme, which would normally allow for glucose to be converted 
into ascorbic acid in the liver (Delanghe, 2011).  Humans who do not consume vitamin C 
for approximately 5-6 weeks have undetectable levels of plasma ascorbic acid (Delanghe, 
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2011).  For this reason, vitamin C intake is so critical that some doctors may recommend 
supplementation beyond just the five fruits or vegetables a day (Omenaas, 2003).  
A tolerable Upper Limit has been established for vitamin C intake, 2000 mg 
intake daily, because vitamin C may cause gastrointestinal problems such as cramping, 
osmotic diarrhea, and bloating (Monsen, 2000; Omenaas, 2003).  Supplemental vitamin 
C may be provided in pills or intravenous supplementation (Padayatty, 2004).  Most 
physicians recommend an intake of 1000 mg daily (Omenaas, 2003).  In the current 
human diet, getting that much vitamin C from food alone is difficult.  In rare cases, some 
individuals may not respond as well to supplementation.  One study found that several 
patients with scurvy had no significant change in plasma vitamin C levels when taken by 
supplement.  However, ingestion of natural lemon juice provided an increase in plasma 
concentrations to rectify the classification of the scorbutic state (Deruelle, 2008).  
Generally, most studies have shown a significant change in plasma vitamin C levels when 
given supplemental vitamin C. 
Functions: antioxidant and enzyme necessity.  One of the crucial actions of 
vitamin C revolves around its antioxidant roles in the blood.  Vitamin C acts as a strong 
reducing agent in the aqueous solutions of the body, primarily including blood and 
cytosol (Gropper, 2013).  The structure of vitamin C permits its actions as a strong 
antioxidant.  Vitamin C donates the two H+ from the hydroxyl groups, forming the 
semidehydroascorbic acid and DHA.  However, the aspect of ascorbic acid that makes it 
such an effective antioxidant is its stability.  When ascorbic acid donates its hydrogens, 
the resulting structures are actually very stable, especially in comparison to the dangerous 
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free radicals in the body (Heo, 2013).  Then, some of the DHA is converted back to 
ascorbic acid, while the majority is metabolized through the actions of hydrolysis (Heo, 
2013).  Some of the free radicals that vitamin C neutralizes includes hydroxyl, 
hydroperoxyl, superoxide, alkoxyl, and peroxyl radicals (Gropper, 2013; 
Shanmugasundaram, 2001). 
In addition to neutralizing ROS, vitamin C’s mechanisms as a reducing agent are 
strongly applicable to other antioxidants.  With the help of niacin, vitamin C takes a 
supporting role in preventing lipid peroxidation.  Niacin helps in the Thiol Cycle, with 
glutathione, and reduces the inactive DHA to the active ascorbic acid.  After vitamin C 
donates the hydrogens to the oxidized vitamin E, vitamin E is able to act as the primary 
lipid antioxidant (Packer, 1979).  Dehydroascorbic acid is reduced by glutathione, 
another antioxidant, via dehydroascorbate reductase.  Glutathione donates its hydrogens 
from GSH to form GSSG.  In fact, the GSH: GSSG ratio is used to measure oxidative 
stress in patients (Urso, 2003).  Vitamin C interacts in many different ways with other 
antioxidants in the body. 
It should be noted that vitamin C is also considered to act as a pro-oxidant in 
addition to its popular antioxidant properties.  The biological decision for vitamin C to 
act as a pro-oxidant specifically depends on the concentrations of free metal ions such as 
iron and copper.  Ascorbic acid can reduce ferric iron (Fe +3) to ferrous iron (Fe +2).  
Unfortunately, in this reaction, the ROS hydroxyl radical O2
− is produced, as well as 
H2O2.  This could potentially pose some problems in lipid peroxidation.  However, this 
would occur if there was a higher concentration of free iron or other metal ions floating in 
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the blood stream.  Free iron in the form of Fe
+3
 can be a threat to the body; the free iron 
can cause critical damage to cellular components.  Patients with iron-binding issues in the 
blood should be cautious about taking vitamin C without an iron-chelator due to possible 
complications regarding the pro-oxidant effects and duties of ascorbic acid in the body 
(Du, 2012).   
The role of vitamin C in collagen formation is tightly associated with the 
symptoms of scurvy, and perhaps the reason for the discovery of vitamin C.  Bleeding 
gums and difficult-to-heal wounds associated with a scorbutic state are reflective of 
insufficient collagen formation.  Ascorbic acid is key for the early steps of collagen 
formation.  It acts as a cofactor in the hydroxylation reactions of proline and lysine which 
will eventually form the stability of the triple-stranded helix formation of procollagen.  
Prolyl hydroxylase and lysyl hydroxylase oxidize iron from  Fe +2 to Fe +3.  Vitamin C 
acts to reduce the iron back to the ferrous state.  The reduction of ferric iron allows for 
the continuation of enzyme activity, resulting in collagen synthesis (Sørensen, 2006).  
Vitamin C is also involved in the formation of carnitine.  A lack of carnitine 
caused by decreased vitamin C status is thought to be the genesis of fatigue or weakness 
in patients with scurvy.  Ascorbic acid is involved in two specific hydroxylation reactions 
in the formation of carnitine in the body.  The two enzyme reactions involve α-
ketoglutarate-dependent dioxygenases.  These enzymes utilize ferrous iron (Fe +2) and a 
reducing agent in the form of ascorbic acid.  In scorbutic Guinea pigs, a decrease of 
muscle carnitine concentrations are found specifically in the skeletal muscle, hepatic and 
renal tissues, and heart muscle (Rebouche, 1991).  Decreases in carnitine concentrations 
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were rectified with supplementation of ascorbic acid (Rebouche, 1991).  Although scurvy 
is more associated with the decreased collagen formation, decreased carnitine is still 
prevalent in scorbutic people.   
Another way vitamin C acts in the immune system is by managing histamine 
levels.  In the body, histamine is a protein made from the amino acid histidine (Gropper, 
2013).  Histamine is crucial for hydrochloric acid release in the stomach from stimulation 
via the vagus nerve.  Then, histamine binds to the H2 receptors allowing acid secretion 
into the stomach (Gropper, 2013; Hagel, 2013).  Additionally, histamine simultaneously 
plays a positive and negative role in immune function.  Histamine causes the bronchial 
smooth muscle to constrict, leading to a cough (Gropper, 2013).  Also, histamine dilates 
the capillaries throughout the body to increase white blood cell delivery to areas of 
infection.  This dilation may then result in other symptoms related to a cold, such as a 
runny nose (Gropper, 2013).  Due to the outcomes of higher histamine levels, 
antihistamine medications are common treatment for cold-like symptoms (De Sutter, 
2012).  However, vitamin C helps to stop the action of histamine once the body has found 
the foreign invader.  As studied in vitro, vitamin C breaks the imidazole ring of 
histamine; this break alters the protein, ceasing its function.  Vitamin C also decreases the 
activity of histidine decarboxylase, the enzyme that creates histamine from histidine 
(Hagel, 2013; Uchida, 1989; Gropper, 2013).  In Guinea pig studies, supplementing 
vitamin C led to a significant decrease in plasma histamine concentration (Hagel, 2013; 
Johnston, 1996).  These Guinea pig studies are relatable to humans because Guinea pigs 
cannot make vitamin C from glucose, like humans.  Human studies have shown a similar 
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result: an inverse relationship between serum vitamin C levels and serum histamine levels 
(Hagel, 2013).  Mega-dosing vitamin C (7.5g) intravenously has shown to decrease 
serum histamine levels by 31.3% in both healthy patients and patients experiencing 
allergy symptoms within 60 minutes of infusion (Hagel, 2013).  Vitamin C’s role in 
decreasing histamine concentrations is relative to its use to fight symptoms from the 
common cold virus. 
Histamine-receptors and histamine levels can be increased by leukotrienes (LT) 
(Ogawa, 2006).  Although vitamin C can influence histamine levels, vitamin C does not 
affect LTs as well.  Ascorbic acid has been shown to decrease Arachidonic Acid, a LT 
precursor, in Guinea pigs.  However, the same activity cannot be said for humans.  
However, synthetic forms of vitamin C have been shown to decrease lipoxygenase 
activity; these enzymes result in damage to the lipid bilayer of cell membranes 
(Mohamed, 2014).  Currently, vitamin C does not have a strong impact on LTs, but can 
decrease the other contributors to inflammation, specifically ROS and histamine. 
Actions in diseases. Vitamin C’s role in diseases is primarily recognized in its 
deficiency disease called scurvy.  Although rare today, humans may still get scurvy if 
their plasma vitamin C drops below 0.2 mg/dL (Jacob, 2002).  
Health professionals have developed a mnemonic of the four Hs to summarize 
scurvy symptoms: hypochondriasis, hematology, hemorrhages, and hyperkeratosis of hair 
(Gropper, 2013).  Hypochondria, a psychological disorder, relates to vitamin C’s role as a 
reducing agent for mineral cofactors or cosubstrates in enzymatic reactions that produce 
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neurotransmitters such as norepinephrine and serotonin (Gropper, 2013).  Hematology 
refers to abnormalities in collagen production and iron absorption that occur when 
vitamin C levels are too low.  This category includes the fatigue that many patients 
experience from decreased carnitine synthesis as well as the increased time in wound 
healing (Gropper, 2013).  Hemorrhages refer to the petechiae, or small red spots on the 
skin from ruptured capillaries, bleeding gums, and bruising.  Collagen formation is 
required to heal or maintain these tissues; when vitamin C is low, the triple helix cannot 
form due to impaired synthesis of hydroxylysine and hydroxyproline and the strength and 
integrity of these vascular tissues are compromised.  Finally, hyperkeratosis relates to the 
weak, corkscrew-shaped hair that grows out of follicles with red-purple bruises at the 
root.  Similar to the hemorrhaging symptom, the lack of collagen formation results in 
structurally weak vessels and hair, which normally rely on collagen formation to maintain 
their shape (Gropper, 2013). 
Apart from the primary function of collagen formation, the high antioxidant 
function of vitamin C is applicable to many studies of other disease states.  Vitamin C 
intake, status, and mega-dose treatment plans have been studied in many problematic 
diseases and conditions humans face today.  Arguably the most prevalent, deadly disease 
humans face today is heart disease; this disease, primarily atherosclerotic in genesis, has 
caused millions of deaths across the world and is the number one cause of death in the 
United States for adults over the age of 65 (Gebhard, 2014; Sharma, 2013).  At first 
glance, vitamin C’s role in preventing and protecting against heart disease and its 
complications seems fairly straight-forward.  Cholesterol builds up in the walls of blood 
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vessels from increased inflammation.  This causes the blood vessels to constrict, 
increasing blood pressure and stressing the myocardial tissue.  Eventually, a cardiac event 
occurs.  Unfortunately, most adults do not know they have increased inflammation until 
the cardiac event happens and they are hospitalized. Because of the high incidence of 
death, a focus in today’s society is to prevent heart disease and decrease the current 
inflammatory state ideally through diet, primarily with antioxidants such as vitamin C, 
and exercise.  However, researchers today are still unsure of ascorbic acid’s action; 
whether vitamin C acts as a primary defense or simply as a cofactor to additional 
medications is still being examined today (Gebhard, 2014). 
Adequate vitamin C intake has been shown to prevent heart disease (Sharma, 
2013).  500 mg supplementation of vitamin C has been shown to significantly lower 
blood cholesterol levels within 30 days (Sharma, 2013).  One study looked at increasing 
fat or cholesterol in the diet and its effect on blood cholesterol levels.  Those who added 
fat or cholesterol to their diets increased their serum blood cholesterol levels.  However, 
when supplemented with vitamin C, participants with an increased fat consumption did 
not have an increase in blood cholesterol levels when supplemented with vitamin C 
(Sharma, 2013).  Vitamin C works in vivo to decrease cholesterol in two primary ways.  
First, vitamin C lowers LDL cholesterol by increasing its excretion to bile. Second, 
vitamin C’s antioxidant capacities prevent oxidation of cholesterol; this oxidation of 
cholesterol can lead to increased build up in the arterial walls (Gropper, 2013; Sharma, 
2013).  Additionally, many studies have indicated an inverse relationship between 
vitamin C and cardiovascular disease risk (CVD); higher intake of vitamin C has been 
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shown in multiple studies to decrease risk of CVD (Ashor, 2014).  Supplementing at least 
700 mg vitamin C daily can attribute to a 25% decrease in risk for coronary heart disease 
(Ashor, 2014).  Overall, studies related to intake of vitamin C have shown that it 
decreases risk for cardiovascular issues.  
An individual’s vitamin C status can also impact a person’s risk for disease or the 
progression of a disease state.  Similar to most nutrients, vitamin C has the most effect on 
an individual when the subject initially has a lower vitamin C status at the beginning of 
the trial.  For example, studies examining effects of vitamin C on endothelial function 
(EF) related to CVD indicated that subjects with adequate vitamin C status had no effect 
on EF markers when supplemented with vitamin C (Ashor, 2014).  However, those who 
had a lower vitamin C status had shown improvement in EF markers.  The dose of 
exogenous vitamin C also impacted EF markers; the higher the dose of vitamin C, the 
greater the response in EF markers (Ashor, 2014).  Evidence of vitamin C status affecting 
the effectiveness of vitamin C treatment has been researched in individuals with genetic 
single nucleotide polymorphisms (SNPs) affecting vitamin C absorption.  One study 
looked at both men and women who had SNP for the SVCT 2 transporter.  These 
individuals would generally have a lower vitamin C status due to a disruption in 
absorption of ascorbic acid into the metabolically active tissues, including the aorta and 
other cardiac tissues (Dalgård, 2013; Gropper, 2013; Hediger, 2002).  The study found 
that women, but not men, with the SVCT 2 SNP had a higher risk for acute coronary 
syndrome (ACS).  This was true for the women who consumed both high (≥127 mg) and 
low amounts of vitamin C (≤100 mg) in the diet, but was not consistent in men (Dalgård, 
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2013).  Sex was an important discriminating factor in the assessment for cardiac risk; the 
researchers concluded that hormonal response may play a role in this SNP, but the direct 
causation is still being researched.  The results of this study suggested a “ceiling” for 
plasma vitamin C levels in this participatory group.  This was further indicated by a lack 
of response to vitamin C supplementation (Dalgård, 2013).  This study found that those 
with a consistently low vitamin C status, due to genetic variation, had an increased risk 
for developing cardiac issues.  Overall, a relationship between vitamin C status and 
cardiovascular health risk is evident. 
 Another deadly, chronic disease that has been the focus of vitamin C research is 
cancer, specifically lung cancer.  Every year, approximately 1.3 million new cases of 
lung cancer are recorded (Luo, 2014).  In 2006, lung cancer was responsible for 162,460 
deaths (Slatore, 2008).  Vitamin C has been examined as a preventive measure and as a 
form of CAM.  In general, research in Vitamin C and lung cancer has shown mixed 
results.  One primary focus with vitamin C and its potential role in lung cancer relates to 
prevention.  Vitamin C’s role has two parts: decreasing damage from cigarette smoking 
and supplemental protection.  Cigarette smoke is thought to be related to 90 percent of 
lung cancers (Slatore, 2008).  Cancer is still eminent after stopping the habit (Slatore, 
2008).  In research, vitamin C is shown to decrease the impact of cigarette smoke.   In 
vivo, cigarette smoke can increase cell proliferation, which increases the activity of 
cancerous cells.  This happens primarily from a compound called p-benzosemiquinone 
(p-BSQ) (Dey, 2011).  The damage to cells occurs when p-BSQ converts to p-
benzoquinone (p-BQ) (Dey, 2011).  A cascade of reactions happen, including excessive 
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epidermal growth factor receptor (EGFR) and Akt, a protein kinase that allows the 
cancerous cells to thrive, which ultimately result in tumors on the lungs (Dey, 2011).  In 
Guinea pig studies, those deficient in vitamin C had extensive tissue damage and tumor 
growth from cigarette smoke.  Vitamin C reduces p-BQ to a hydroquinone, which renders 
it inactive (Dey, 2011).  Because of its clear role in decreasing damaging semiquinones, 
vitamin C supplementation’s effect on lung cancer risk has been examined through 
studies.  In those with lung cancer, serum vitamin C levels are significantly lower than 
healthy control patients (Mahdavi, 2009).  Those with lung cancer had 0.13 ± 0.03 mg/dL 
vitamin C while the healthy counterparts had 0.89 ± 0.07 mg/dL (Mahdavi, 2009).  
Additionally, malondialdehyde is significantly higher at 4.6 ± 2.4 nmol/L in those with 
cancer compared to 0.27 ± 0.11 nmol/L (Mahdavi, 2009).  Malondialdehyde is associated 
with lipid peroxidation and DNA malformation, which is caused by uncontrolled ROS 
activity (Mahdavi, 2009).  The lower serum vitamin C level may be attributed to the 
higher malondialdehyde.  Since those with cancer had such low levels of vitamin C, 
supplementation is thought to reduce the risk of getting lung cancer due to vitamin C’s 
antioxidant capacity.  However, studies have shown no difference in risk.  In the VitAL 
(Vitamins and Lifestyle) study, 77126 subjects were followed for 4 years and 
supplementation regimen was documented.  521 of all subjects developed lung cancer 
(Slatore, 2008).  The researchers found there was no significant difference in risk in those 
who took 1000mg supplemental vitamin C and those who did not.  The study did note 
that there may be promise in male subjects with vitamin C supplementation and 
decreased cancer risk (Slatore, 2008).  Another study confirmed this observation in males 
23 
 
over females, noting that for every 100mg vitamin C taken, the risk for getting cancer 
decreases by 7% (Luo, 2014).  The study also discussed that those who consumed 
vitamin C in the form of fresh fruits and vegetables do have a protective factor against 
getting lung cancer (Slatore, 2008).  Overall, it seems that the form of consumed vitamin 
C has an effect on cancer risk, but vitamin C in general has been shown to decrease the 
dangerous effect of cigarette smoking.  
 Vitamin C has also been studied as a form of CAM in those who do have lung 
cancer already.  In cancer patients, high-dose vitamin C is administered intravenously 
(IV), ranging from 5-50g (Mikirova, 2012).  Inflammation in the body is typically 
associated with increased cancer cell growth.  One study examined the effect of IV 
vitamin C on inflammation levels; C-reactive protein and pro-inflammatory cytokines, 
such as IL-2, IL-8, and TNF-α, were examined.  An inverse correlation has been found in 
inflammatory levels and tumor markers.  The study found that vitamin C did have a 
significant effect on CRP levels and inflammatory status (Mikirova, 2012).  This study 
shows that vitamin C may be a suitable complementary therapy to other cancer treatment 
plans.  There is not enough evidence to use vitamin C as a sole treatment for cancer, 
although studies are still being completed.   
Vitamin C has been recently studied in relation to protection against gout.  
However, the results are varied.  Gout, in general, is a buildup of uric acid in the body 
(Stamp, 2013, Choi, 2009).  Gout is controlled by lowering the serum urate to less than 
0.36 millimoles per liter (Stamp, 2013).  There are two main ways to decrease serum 
urate in the body.  The first is to decrease the production of uric acid by medications that 
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inhibit the xanthine oxidase enzyme (Stamp, 2013).  The second is to increase the 
excretion of urate from the body; this is achieved by slightly manipulating the kidneys 
through medical treatment (Stamp, 2013).  However, vitamin C has been proposed as an 
alternative way to manage gout.  Vitamin C competes with uric acid in the proximal 
tubules of the kidneys as both utilize anion-exchange transport mechanism for 
reabsorption; this increases reabsorption of vitamin C and excretion of uric acid in the 
urine (Choi, 2009).  One small study examined the effects of mega-dosing vitamin C and 
its effects on serum urate concentrations.  There was a notable increase in urate excreted 
via urine.  Interestingly, the serum urate concentrations did not show any significant 
change (Stamp, 2013).  On the other hand, another randomized controlled trial showed a 
statistically significant 0.02mmol/L decrease of serum urate in healthy individuals when 
supplemented 500mg vitamin C daily for 60 days (Stamp, 2013).  In the same study, the 
subgroup that had baseline serum urate levels > 0.42 mmol/L had a reduction of 0.09 
mmol/L; this change was four times greater than the general population, indicating that 
those with gout may be likely to see a change in serum urate concentrations (Stamp, 
2013).  However, another study that compared 20 subjects given daily 500 mg vitamin C 
to 20 subjects given standard xanthine oxidase inhibitor allopurinol (50-100mg, 
depending on the subject’s physician and renal status), which inhibits uric acid 
production, did not find a clinically significant decrease in serum urate.  It should be 
noted that this study still saw the same change from baseline (0.02 mmol/L).  The 
researchers noted that 500 mg/day of vitamin C, which is the common dosage in these 
trials, may be too low to see a clinically significant change in serum urate (Stamp, 2013).  
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In terms of preventing gout, one 20-year longitudinal study of 51529 males in health 
profession found that those who consumed more total vitamin C (via food or supplement) 
had a statistically significant lower risk for developing gout than those who had less than 
250 mg/day (Choi, 2009).  Interestingly, the males who consumed over 1000 mg/day 
vitamin C had no significant change than those who consumed between 500 and 999 
mg/day.  This study concluded that an intake of 500 mg/day vitamin C is strongly 
associated with a decreased risk for gout (Choi, 2009).  Altogether, current usage of 
vitamin C as alternative medicine is still mixed in research. 
Review of Asthma 
Definition and diagnosis. The official diagnosis of asthma occurs with the 
clinical assessment of a licensed medical doctor in tandem with laboratory results.  
Patients with asthma will show the common symptoms, which include cough, chronic 
wheezing, shortness of breath, and tightness in the chest.  Any extent of these symptoms 
may be present, including a small cough.  After observation of the symptoms, pulmonary 
function tests (PFT) will show what is called reversible airflow obstruction. Decreased 
FEV1 and FEV1:FVC ratio is indicative of airway obstruction.  Because asthmatics are at 
a state of chronic inflammation, elevated IgE and eosinophilia will be present, but not 
solely indicative of asthma.  Additionally, a chest x-ray may indicate asthma-induced 
inflammation.  One popular test that can be run is the methacholine provocation test, also 
called the histamine challenge test.  All tests together can indicate if a patient has asthma 
(Omenaas, 2003). 
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The diagnosis of asthma is not as easy as it appears.  One common saying among 
respiratory experts is that “all that wheezes is not asthma” (Omenaas, 2003).  Some other 
disorders may copy the signs and symptoms of asthma; many of these are considered to 
be much more serious than treatable asthma.  These mimicking conditions include 
allergic inflammation of the sinuses, congestive heart failure, pulmonary embolism, and, 
perhaps the most commonly confused condition, chronic obstructive pulmonary disorder 
(COPD) (Corren, 2013).   The difference between asthma and COPD is simple: COPD is 
irreversible (Omenaas, 2003). Asthma symptoms are completely, or at least partially, 
reversible. Analyzing whether or not something is irreversible takes some time.  
Therefore, many studies go ahead and couple COPD patients and asthma patients 
together. 
The definition of asthma has changed over time.  Previously, most definitions 
focused on the association of airway hyperresponsiveness, a condition where the human 
airway abnormally constricts from a stress response or inhaled allergens.  Today, the 
focus of what classifies a patient as having asthma has shifted.  Asthma is now 
considered a “primary inflammatory disease of the airways, with clinical manifestations 
of increased bronchial hyperreactivity and airflow obstruction due to the inflammation,” 
(Wilkins, 2009).  Basically, asthmatics live in a constant state of inflammation, 
particularly in the trachea.  This inflammation can lead to blocked airways, preventing 
normal respiration.  Asthma, along with COPD, is one of the most common conditions 
under the larger spectrum of obstructive lung diseases, which also includes cystic fibrosis 
(Wilkins, 2009).   
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Asthma has been around for centuries.  Interestingly, the term asthma derives 
from the Greek word for “panting”.  Hippocrates gave the name asthma to the condition 
around 400 B.C.  One early 20
th
 century book called Principles and practice of Medicine 
described asthma as “swelling of the nasal or respiratory mucous membrane, increased 
secretion, and…spasms of the bronchial muscles with dyspnea, chiefly expiratory,” 
(Maslan, 2014).  The author of the book, Sir William Osler, also indicated that treatment 
could happen with tobacco-based cigarettes.  Obviously, this treatment has been 
dismissed, as smoking has shown to increase inflammatory conditions leading to 
asthmatic episodes (Omenaas, 2003).  
Asthma is not universal among all patients.  A group of asthmatics can have a 
myriad of different experiences.  However, attempt has been made to identify common 
experiences among asthmatics.  Through analysis of common themes among patients, 
different subgroups of asthmatic patients can be created (Wilkins, 2009).  Generally, 
these themes revolve around the different phenotypes of asthmatic patients, or outward, 
observable characteristics.  One theme that has been examined is whether the patient has 
atopic asthma or not.  Atopic conditions are genetic-based allergic reactions that happen 
immediately after short exposure to a certain antibody (Omenaas, 2003).  Another theme 
that is looked at is the time at which asthma began.  More than often, asthma begins in 
childhood; this onset is considered early.  In less frequent cases, asthma may occur later 
in life (Wilkins, 2009).  The need for daily or emergency medication can separate 
asthmatics.  Additionally, analysis of sputum to see the differences at the cellular level 
can differentiate asthmatics from one another.   The sputum analysis can show 
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differences in antibodies present as well as inflammatory markers such as interleukin (IL) 
(Wilkins, 2009).  Other themes among asthma patients include any decrease to lung 
function and Nitric Oxide (NO) expiration.  The level of NO exhaled can show a 
correlation with IL-13 activity (Wilkins, 2009).   
Very recently, more cases of exercise-induced asthma in adults have appeared.  
However, the term “exercise-induced asthma” is no longer used.  Rather, professionals 
name this condition as exercise-induced bronchoconstriction (EIB).  This is a reversible 
tightness of the airways brought on by at least 5-10 minutes of strenuous exercise.  
Common exercises that induce this condition include running and cycling.  It can occur in 
swimmers, however much less often. Ninety percent of people with the diagnosis of 
asthma later in life show exercise-induced bronchoconstriction as one of the first signs of 
their asthma.  EIB can impact all athletes on any skill level, from novices to elites.  
Diagnosis of this condition is done with an exercise challenge on a treadmill or bike.  EIB 
affects 7-20% of the general population, and thus is crucial in the discussion of asthma 
(Randolph, 2009). 
Assessment tests.  Some people with asthma have decreased pulmonary function 
as a result of the constant inflammatory condition (Wilkins, 2009).  Often, pulmonary 
function tests (PFTs) are used in asthma research to determine the success of 
interventions (Bender, 2004).  However, other forms of tests, including Histamine 
Challenge and the Rint technique can also assess asthma status.  Specific pulmonary 
function tests look at expiratory air and its volume or contents. 
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Spirometry looks at a multitude of pulmonary function tests useful for analysis of 
the severity of many different obstructive lung diseases; asthma falls under this category 
of respiratory diseases (Wilkins, 2009).  Spirometry can also diagnose obstructive 
diseases (Mayo Clinic Staff, 2014). One pulmonary function test included in spirometry 
used is FEV1.  FEV1 is forced expiratory volume at 1 second.  This measures the 
maximum volume of air a patient expires during the first second of a forceful exhale 
(Wilkins, 2009).  In many research studies, FEV1 is used to validate alternative tests to 
spirometry (Kooi, 2006).  Asthmatics will find a decrease in FEV1 as the severity of the 
disease increases (Oakes, 2008). Another PFT included in spirometry is FEF, or Forced 
Expiratory Flow.  FEF measures the speed of the expired air in a certain amount of time.  
FEF tests can range from 25 to 1200 milliseconds (Wilkins, 2009).   FEF will decrease in 
severe asthma (Oakes, 2008).  These tests included in spirometry generally decrease in 
asthmatics due to the increase in airway obstruction and resistance (Wilkins, 2009).  
However, some PFTs can increase in asthmatics; most of these measure lung volume 
(Oakes, 2008).  While the rates of speed and air expired generally increase, the volume of 
the lungs, interestingly, increases in the obstructive diseases.  This happens because the 
body is trying to compensate for the difficulty breathing (Oakes, 2008; Wilkins, 2009). 
One of the PFTs that reflect this is RV, or Residual Volume.  An increased RV can 
indicate the presence of air trapping, which happens in obstructive diseases.  Because the 
body cannot expire the normal amount of volume, air is “trapped” in the lungs (Wilkins, 
2009).   Table 2 shows the trends in asthma with common PFTs. 
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Table 2.  
Pulmonary Function Tests (Oakes, 2008) 
Pulmonary Function Tests Results in Asthma 
RV  Increase 
TLC (Total Lung Capacity) Slight increase but within normal range 
FEV1 Decrease 
FEF 25-75 Decrease 
FEF 200 – 1200 Slight decrease but within normal range 
 
Another test that can measure the activity of obstructive diseases is the Histamine 
Challenge.  The Histamine Challenge test involves administered exogenous 0.06 to 3.9 
µmol histamine in the form of histamine acid phosphate (Backer, 1991).  Prior to 
administration of histamine, a baseline test of lung function is completed.  Then, PFTs 
are completed after each dose.  A Histamine Challenge can show bronchial 
hyperresponsiveness when PFTs, such as FEV1, decrease.  The bronchial 
hyperresponsiveness correlates with the asthmatic condition.  This test has been shown to 
be fairly accurate, with a 95% confidence interval (Backer, 1991; Schoeffel, 1980).  Most 
asthmatics will show a significant decrease between 2 and 20% of baseline FEV1 
(Backer, 1991).  The Histamine Challenge test is a tool that can show how responsive an 
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asthmatics airway is to foreign particles in the body. An exercise challenge test may be 
completed as well, but is not as reliable as the Histamine Challenge (Schoeffel, 1980).  
Most Histamine Challenge and exercise challenge tests have been researched for disease 
diagnosis in children with asthma rather than adults (Haby, 1994).   
PFTs may be difficult to obtain in children, due to the discomfort of the mask and 
its effect on normal breathing (Kooi, 2006).  When a mask is used, PFTs can vary as 
much as 10% (Child, 2005).  To rectify this complication, another test can be performed.  
The Interrupter Technique (Rint) is used to measure the pressure of the mouth.  This 
method was discovered in 1927 by Von Neergaard (Child, 2005).  Recently, a portable, 
inexpensive device has been created.  The device is essentially a handheld box, about the 
size of a phone, with a short tube.  The patient puts his or her mouth on the tube and the 
patient breathes as normal as possible.  Five to ten measurements are taken and the results 
are compared to the equation: Expiratory Rint (kPa · L
-1
 ·s) = 1.972  - 0:00992 x standing 
height (cm) (Kooi, 2006; Child, 2005). Although much less invasive than spirometry, the 
Rint method has been shown to be as valid as FEV1 (Kooi, 2006; Child, 2005).  The Rint 
technique has shown significant differences in healthy versus asthmatic patients (Kooi, 
2006).  Patients as young as 2-years-old can utilize the Rint technique.  Although not 
completely established, current research is determining whether or not the Rint technique 
can be used to diagnose asthma in children (Child, 2005).   
Etiology of symptoms. Although symptoms may differ between individuals, the 
most common clinical symptoms of asthma are shortness of breath, tightness of chest, 
wheezing, and coughing (Ogawa, 2006). These symptoms are related to a 
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hyperresponsive airway, chronic inflammation, and bronchoconstriction.  The primary 
components of these processes are leukotrienes and their stimulation of histamine.   
Leukotrienes (LT) are made from phospholipids and enzymatic reactions.  
Phospholipase A2 releases arachidonic acid, which is then oxidized by 5-lypoxygenase at 
C-5 to make leukotriene A4, which is unstable.  Leukotriene A4 is then converted to 
CystLT (Liu, 2015).  This specific type of leukotriene is most active in asthma (Liu, 
2015).  Therefore, some asthma research has examined the effect of an anti-LT 
medication, such as zafirlukas, montelukast and zileuton, to reduce asthmatic episodes 
(Wenzel 2003).  Research has shown these drugs can improve FEV1 (7% - 15% increase) 
while also decreasing episodes of nocturnal asthma symptoms by 30-40% (Wenzel, 
2003).  However, some research has also shown no improvement when coupled with a 
standard corticosteroid, which do not decrease CysLT levels (Ogawa, 2006).  CysLTs 
specifically work in asthma by stimulating smooth muscle in the airway, which then 
increases inflammation by secreting cytokines, such as TH2, and chemokines that increase 
generation of IL-5 and TNF-α from the mast cells (Ogawa, 2006).  They also promote 
inflammation by increasing histamine receptor expression (Ogawa, 2006).  Research of 
anti-LT medications have shown no significant decrease in histamine receptors compared 
to corticosteroid therapy.  Additionally, LTs increase eosinophil expression, promote 
chemotaxis (by stimulating endothelial cells to make platelet activating factor), and 
support the survival of these cells (by promoting progenitor cell activity and thus, 
increasing eosinophilopoesis), thus promoting more asthmatic reactions in the near future 
(Ogawa, 2006).  There is a strong correlation between eosinophilic inflammation of the 
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airway and the severity of asthma (Liu, 2015).  CysLTs are also active in cell remodeling 
of the airway by promoting mitogen-stimulated lung fibroblasts.  This condition is very 
common in asthmatics (Ogawa, 2006). 
While LT activity is very strong and prominent in the asthma syndrome, not all 
asthmatics are responsive to anti-LT drug therapy.  Approximately 6% of asthmatics have 
a genetic polymorphism that results in decreased productions of LTs (Ogawa 2006).  
Asthmatic smokers may have an increased benefit from anti-LT medications.  
Additionally, a correlation between urinary LT and effectiveness of treatment has been 
established; those patients with an increase in urinary excretion of LTs would have a 
strong reaction to anti-LT medications (Ogawa, 2006).  Some patients may see 
improvements by pharmaceutically-mediated decreased bronchoconstriction: either by 
corticosteroids or by inhibiting the effects of LTs by anti-LT medications. 
Prevalence and economic impact.  Asthma is a dangerous medical condition that 
affects multiple populations worldwide (Milan, 2013).  
In the United States, 1 in 12 adults and 1 in 11 children have been diagnosed with 
asthma by a medical doctor (Urbano, 2008).  That means in the typical elementary 
classroom size (approximately 30), 3 children have difficulty breathing on a daily basis.  
Asthma affects women ages 18-24 more commonly than any other age group.  Also, 
African-Americans are more likely than Caucasians to have asthma (Urbano, 2008).  
Asthma has a surprisingly high mortality rate; every day, 9 people in the United States 
die from asthma-related complications (Urbano, 2008).  In 2010, approximately 3500 
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deaths can be attributed to complications associated with asthma (Urbano, 2008).  The 
frequency of this disease is highly indicative of its economic effect on the United States. 
Asthma’s total cost on the United States is $56 billion annually (Urbano, 2008).  
The main two components of this expense are hospital visits and emergency-room visits.  
In 2009, 1.9 million emergency-room visits and 8.9 million doctor visits were related by 
asthma symptoms.  Asthma also attributed to 479,300 hospitalizations in 2009 (Urbano, 
2008).  The high rate of visits may be attributed to a few factors.  One factor may be that 
asthmatics tend to have an overly high level of confidence that they are managing their 
asthma (Randolph, 2009).  Because of this, a clear decline in medication use is evident.  
Among children, it has been found that prescribed daily medications are used only 40-
48% of days per year (Center for Disease Control and Prevention, 2013).  Asthmatics 
may not feel like they need their medication, so they do not follow directions for optimal 
use.  This may lead to sudden attacks, thus requiring a trip to the emergency-room, 
followed by a trip to the doctor (Center for Disease Control and Prevention, 2013).  
Another factor may be unclear causes of asthma attacks.  Many asthmatics only know a 
few of their triggers.  New environments or experiences may trigger an unforeseen attack 
(Omenaas, 2003).  Much work is being done to try to decrease medical visits caused by 
asthma (Karaca-Mandic, 2012). 
Another cost of asthma is the medication itself.  In general, people with asthma 
have an annual household income less than $75,000.  Although this is not poverty level, it 
still indicates that money may be more of a concern for these individuals.  Asthma 
medications are another bill that needs to be budgeted.  As asthma medications increase 
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in effectiveness, the prices increase (Karaca-Mandic, 2012).  The cost is also an ethnicity 
issue.  1 in 5 Hispanics and 1 in 4 African-Americans cannot afford asthma medications 
prescribed by their doctor, even off-brand medications (Urbano, 2008).  For children with 
asthma, average out of pocket expenses are $154 yearly.  With the low adherence to 
medication, this may reflect a possible waste (Center for Disease Control and Prevention, 
2013; Karaca-Mandic, 2013).  However, the low adherence may be due to the expense of 
the medication.  Parents may try to stretch out medications to last longer than the typical 
30 days (Center for Disease Control and Prevention, 2013).  Ironically, children can 
identify asthmatic symptoms better than adults (Urbano, 2008).  Therefore, ignorance 
may play a huge factor in the medication adherence and possible cause of an increase in 
medical visits.  1 in 5 asthmatic children went to the emergency room for asthma-related 
issues in 2009 (Urbano, 2008).   
Finally, the cost of asthma is also reflected in missed work or school days.  In 
children, 50% of those with asthma miss at least one day of school because of their 
severe asthma symptoms (Urbano, 2008).  Although one day of missed school does not 
seem like much, it may hinder their learning progression.  Additionally, working adults 
may have to stay home to care for their children on sick days, causing a measurable 
financial loss.  In older asthmatics, 1 in 3 working adults have to miss at least one day of 
work due to asthma issues (Urbano, 2008).  Since most asthmatic adults have a lower 
household income, finances is already a concern.  One missed day of work can stress 
finances even further.  The cost of asthma is multi-factorial and extremely high.   
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Triggers. Asthma symptoms can be triggered by a multitude of forces.  The most 
commonly assumed triggers are physical allergens, such as animal hair or foreign air 
particles (Ritz, 2006; Wood, 2007).   However, emotional and psychological factors are 
currently emerging as recognized huge players in asthma control.  Research has shown 
that perceived control of asthma symptoms can have a huge impact on quality of life 
(Ritz, 2006).  
Most asthma triggers are determined by questionnaires.  However, a large range 
of results occur from questionnaires.  A review of different questionnaires has found that 
4 to 74% of triggers are captured by questionnaires (Ritz, 2006).  Due to the large range, 
a higher quality survey is necessary.  The Asthma Trigger Inventory (ATI) is a detailed 
questionnaire that covers 32 items on a 5-point rating scale: 0=never, 1=rarely, 
2=sometimes, 3=most of the time, 4=always (Ritz, 2006).  The ATI evaluates six 
overarching topics of common triggers; these triggers include emotional/psychological 
(including stress), animal, pollen, exercise, air irritants, and infection (Ritz, 2006).   
A study of the ATI had many findings.  One primary discovery related to 
psychological triggers.  Psychological triggers have been found to have a significant 
decrease in overall health and quality of life (Ritz, 2006).  This finding is key as 
psychological triggers were often overlooked in discussions with primary physicians 
(Ritz, 2006; Wood, 2007).  Another finding was that animal allergens significantly 
increased required hospital care compared to the other triggers (Ritz, 2006).  In general, 
there seems to be a synergistic effect of the triggers; multiple trigger types are 
interconnected in causing asthma symptoms.   
37 
 
Different populations were studied with the ATI for the internal and external 
validity of the questionnaire.  Gender may play a role in triggering symptoms.  Females 
are more likely to have triggers from physical activity, pollution, and infection over their 
male counterparts (Wood, 2007).  This difference seems to stem from gender psychology; 
males are “taught” to ignore symptoms or “get over” the symptoms.  The culture of males 
versus females has shown results in what triggers an asthma attack (Wood, 2007).  In 
addition to gender having an effect, different ethnicities have different reactions to 
triggers.  Non-Caucasian asthma patients have an increase in asthma symptoms from 
physical activity triggers and pollution (Wood, 2007).  Finally, when asthma is diagnosed 
can impact the susceptibility of triggers.  Those who are diagnosed earlier in life, early 
onset of asthma, are more reactive to all six types of triggers than those who were 
diagnosed later in life (Wood, 2007).  Since asthma is a highly-individualized disease, the 
ATI can help in the discussion of asthma control with the primary care physician. 
Nutrient status.  Much research has been completed analyzing the overall 
nutrient status in asthmatics.  Some groups of nutrients are similar between equivalent 
normal subjects and asthmatics.  However, some nutrients, antioxidants in particular, are 
generally lower in asthmatics than their equivalent control counterparts.   
Perhaps the most critical nutrient deficit in asthmatic individuals relates to 
micronutrients.  One study examined the intake of common antioxidants over a 7-day 
food diary and incidences of asthma attacks during the previous 12 months.  This study 
found that, on an individual basis, decreased intake of vitamin C, folate, calcium, and 
manganese were associated with increased asthma.  Additionally, this study examined the 
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relationship between plasma vitamin C concentrations and increased risk of asthmatic 
attacks.  Although the control and the study group had fairly equal plasma vitamin C 
levels, the plasma levels were significantly lower in those who had symptomatic asthma 
rather than those who had asymptomatic asthma (Bender, 2004).  
In addition to micronutrient status, intake of polyunsaturated fatty acids has an 
effect on asthmatic conditions.  The omega-6 PUFA’s, such as arachidonic acid, are 
associated with inflammation while the omega-3 PUFA’s, such as eicosapentaenoic acid 
and docosahexaenoic acid, are associated with anti-inflammatory status.  Since the 
United States consumes a diet with a higher omega-6:omega-3 ratio, this should have a 
place in asthma research.  Some studies have shown that consumption of omega-3 PUFA 
in the form of fish has been shown to decrease the risk for developing asthma in adults.  
However, it may actually increase the risk of developing asthma in children.  The 
association is not quite clear.  Additionally, increased consumption of omega-6 in the 
form of margarine has been shown to increased risk of wheezing symptoms of asthma.  
Due to the conflicting nature of the results involving studies with PUFA’s, no 
recommendations for a possible intervention can be made (Patel, 2006). 
Perhaps the most critical component of nutrient status in asthmatics revolves 
around antioxidants. In fact, this dietary association with asthma is one of the most well-
studied (Bender, 2004).  Many studies look at vitamin C status and consumption in 
relation to asthmatic symptoms.  Studies have shown that lower vitamin C status is 
associated with lower lung function levels in children (Bender, 2004).  Higher intakes of 
vitamin C were associated with better FEV1 scores.  A double-blind crossover study 
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examined exercise-induced bronchoconstriction (EIB) protection through vitamin C 
supplementation.  A group of 8 patients who have had EIB in previous exercise 
experiences were given 1500mg vitamin C per day or placebo.  PFTs were measured 
before and after exercise.  One week later, the groups were switched, making it a 
crossover study.    The study found that the treatment diet decreased the fall of PFTs post-
exercise (-6.4±2.4%) whereas the placebo group fell much worse (-12.9 ±2.4%) 
(Tecklenburn, 2007).  Obviously these results are not fully conclusive.  In fact, the recent 
Cochrane Review states that there is insufficient evidence to clearly link vitamin C with 
asthma (Milan, 2013). 
Increased risk for colds.  Although little research has been done on asthmatics 
and colds, the two conditions are highly related (Milan, 2013).  However, some research 
has indicated that asthmatics have increased worsening of symptoms following a cold.  
One study followed 413 adults with asthma.  Using the Wisconsin Upper Respiratory 
Symptom Survey-21 (WURSS-21), they calculated the severity of the colds.  They also 
used the mini-Asthma Control Questionnaire (mini-ACQ) to evaluate possible changes in 
stability of their asthma.  The researchers found that the more severe the symptoms of the 
first two days of the cold will predict a decrease in control of the patient’s asthma.  From 
these results, it is very important for asthmatics to avoid getting the common cold.  
However, research preventing a cold is still mixed, giving asthmatics an unclear 
understanding of how to prevent worsening of their asthmatic symptoms (Allan, 2011). 
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Asthma and Vitamin C.   
Understanding the common functions of vitamin C in the body propels research 
for understanding the role of vitamin C in specific diseases.  Generally, most vitamin C 
research in disease is fairly controversial.  Vitamin C has mixed results in cancer 
treatment studies (Du, 2012).  Most progress is made regarding certain types of 
individuals with diseases.  For example, vitamin C has proven to significantly reduce the 
risk developing the common cold specifically in populations of athletes and military 
personnel (Milan, 2013).   
The current research shows success of vitamin C in reducing the incidence of 
colds in highly stressed populations, specifically military cadets and athletes.  There are 
major physiological differences between stress from asthma and exercise-induced stress.  
Stress is simply defined as any internal or external triggers or conditions that affect 
homeostasis (Mastorakos, 2005).  Asthmatic stress is primarily related to uncontrolled 
ROS and eosinophilic action in the lungs leading to obstructive episodes (Liu, 2015).  On 
the other hand, exercise-induced stress is very different physiologically, and this stress 
includes multiple organ systems (Mastorakos, 2005).  ROS are produced during exercise; 
2-5% of oxygen used in the mitochondria during exercise produces ROS (Urso, 2003).  
The central nervous system plays a major role in stress as well.  Norepinephrine, typically 
associated with the fight-or-flight response, is increased to increase heart rate and 
attention or focus (Mastorakos, 2005).  The hypothalamic-pituitary-adrenal (HPA) 
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reactions lead to increased cortisol; this steroid hormone is primarily increases blood 
sugar and metabolism while also suppressing the immune system (Cevada, 2014).   
The success of vitamin C supplementation in these populations can relate to the 
physiological stress process.  Vitamin C is required for the production of norepinephrine 
(Gropper, 2013).  As more vitamin C is used for exercise-induced stress, more is 
absorbed to replenish the needs.  Also, the release of cortisol increases metabolism, thus 
requiring more vitamin C to keep the mineral cofactors reduced (Gropper, 2013).  
Additionally, the immune system is suppressed during times of stress, leading to 
increased needs for antioxidant vitamins (Gropper, 2013).  Athletes and military cadets 
utilize vitamin C much more frequently due to their daily stresses and initiation of the 
physiological stress response.   
Asthma is another condition with highly mixed results from treatment with 
vitamin C.  Utilizing vitamin C for treatment of asthma symptoms stems from the ideal 
conditions where vitamin C has a large room for effect.  The role of vitamin C in the 
body, mostly as an antioxidant and as a nutrient recycler, relates strongly to the 
conditions of a typical adult asthmatic.   
Asthmatics typically have low intakes of vitamin C.  One study showed that 
decreased consumption of vitamin C in the diet has a positive relationship with forced 
vital capacity (FVC), or how much air a patient can expire as quick as possible (Ochs-
Balcom, 2006; Allen, 2009).  The FVC test is done in asthmatics to determine 
significance of symptoms.  Therefore, increased vitamin C consumption should ideally 
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result in increased respiratory function.  However, reported intake of vitamin C alone has 
high room for error, due to the reactive abilities of vitamin C and errors in reporting 
systems (Ochs-Balcom, 2006).  Vitamin C is highly reactive in the air, making estimates 
in food difficult.  Additionally, patients frequently overestimate intake of fruits and 
vegetables when asked by medical professionals, making the accuracy of food diaries 
questionable (Gropper, 2013).   
In addition to general low intake of vitamin C, asthmatic adults generally have 
low plasma vitamin C levels.   Decreased serum vitamin C levels are strongly associated 
with oxidative imbalances (Ruprai, 2011).  Asthma is an inflammatory disease.  
Therefore, more vitamin C is required to try to subdue the inflammation by its actions as 
a secondary lipid antioxidant by regeneration of vitamin E (Ruprai, 2011). 
Another condition of asthmatics that show a large possibility of a relationship 
involves the higher incidence of reactive oxidative species (ROS).  Asthmatic adults have 
been shown to have significantly increased levels of ROS in the blood.  Additionally, 
enzymes that are utilized to neutralize ROS, such as superoxide dismutase, and other free 
radical scavengers in the blood were noticeably lower in asthmatics than normal 
population.  Clearly, in tandem with the common actions of vitamin C, ascorbic acid has 
the potential to show a change in the status of asthmatics.  Perhaps with vitamin C, ROS 
and inflammation causing symptoms in asthma would significantly decrease, thus 
lowering risk for mortality related to asthma (Shanmugasundaram, 2001). 
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The potential usefulness of vitamin C is further supported by the assessment of 
medication use in asthmatics with ascorbic acid supplementation.  One study examined 
the relationship between vitamin C supplementation and corticosteroid use in asthmatic 
adults.  Compared with placebo and magnesium supplementation, participants in the 
vitamin C supplementation groups showed a significant decrease in corticosteroid use by 
49 doses unused (Fogarty, 2006).  The decrease in medication use in asthmatics in the 
vitamin C group show potential causal relationship.    This association is critical, 
especially with the considerable economic impact of asthma. 
Vitamin C supplementation to treat asthmatic symptoms has been explored in 
research.  Nutrient supplementation is considered to be Complementary and Alternative 
Medicine.  As shown with the results of the study decreasing corticosteroid use, vitamin 
C can potentially take the place of pharmaceuticals prescribed by medical doctors.  It is 
important to note that 41% of asthma patients in the United States and 59% of asthma 
patients in the United Kingdom use some form of Complementary and Alternative 
Medicine (CAM) (Brutsche, 2002).  However, most success stories with utilizing CAM 
in asthma were cases where CAM was used in addition to classical medications.  
Additionally, popularity cannot be correlated with safety; studies looking at CAM versus 
traditional medication are difficult to achieve due to placebo effects and inability to 
perform randomized controlled trials ethically (Brustsche, 2002). 
To test the theory behind vitamin C’s usefulness in decreasing asthmatic 
conditions, animal studies must be completed.  One study examined a mega-dose of 
vitamin C to combat the inflammatory conditions of asthma.  Experimental mice were 
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injected with pharmaceutical drugs to replicate the conditions of asthma.  After the mice 
became “asthmatic”, 3-5 mg of vitamin C were administered 6 consecutive days.  The 
results had shown a significant decrease in inflammatory cells in the lungs of the mice 
(Jeong, 2010).  Only one human study, done in Nigeria, has shown significant changes 
from vitamin C supplementation on lung function tests in asthmatics (Jeong, 2010; Choi, 
2009).  It has been assessed that there is not enough information in vitamin C studies to 
determine significant effects on asthmatic populations (Milan, 2013). 
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CHAPTER 3: METHODS 
Participants 
 The study was advertised through available list serves (APPENDIX A).  
Interested candidates followed a provided link on the email that will direct them to 
surveymonkey.com (APPENDIX B).  Those whose survey answers match the candidate 
requirements were then emailed and asked to come to the Downtown Phoenix campus for 
an initial blood draw.  The subjects of the study are adults, ages 18 to 55 years, who have 
been diagnosed with asthma by a Medical Doctor.  The subjects must also have a plasma 
vitamin C level ≤ 0.75 mg/dL.  This indication of normal to low vitamin C status is 
critical for showing the effects of vitamin C supplementation on lessening symptoms of 
asthma or the common cold.  Smokers were excluded, due to the increased antioxidant 
requirement (Omenaas, 2003).  Additionally, those partaking in excessive exercise, such 
as training for a marathon, were also excluded because of the high correlation of exercise 
and asthmatic symptoms (Omenaas, 2003).  Vegans were also excluded from the study 
because the placebo pills and vitamin C supplement contain gelatin-based capsules.  To 
prevent any possible discomfort, gluten intolerant individuals were excluded since the 
placebo pill contains wheat flour.  Flu shots could potentially also interfere with the 
susceptibility of contracting a cold.  However, we did not exclude for this.  One clear 
exclusion criteria was any vitamin C supplement use within the past 30 days.  This time 
period is adequate to allow the additional vitamin C to be excreted from the body 
(Gropper, 2013).  IRB approval of this study is complete, and written consent was 
obtained from all participants (APPENDIX C).   
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Study Design 
 The study design was a double-blind randomized controlled trial.  There was a 
treatment group (1000 mg daily vitamin C) and a control group (placebo).  1000 mg of 
vitamin C were used to ensure all treatment participants had absorption of vitamin C.  
Subjects were stratified by age, gender, BMI, and vitamin C status and randomized by a 
third party into the two groups.  As the study was double-blinded, the neither the subjects 
nor the researchers knew which specific intervention any subject underwent.  The 
treatment of the study included 500 mg vitamin C supplement consumed twice daily with 
meals.  The placebo capsule was indistinguishable from the vitamin C capsule and 
contained white flour.  The study lasted for 8 weeks.  Interested participants took a 
survey through surveymonkey.com (APPENDIX B) in the month of December.  
Qualified individuals were contacted and invited to come to the Downtown Phoenix 
campus to the ABC 1 building to sign consent (APPENDIX D), to draw blood after a 5-
hour fast, and complete a health history questionnaire (APPENDIX E).  After measuring 
plasma vitamin C levels, subjects were asked to come to pick up questionnaires for 
Weeks 1-4 and capsules to consume twice daily (APPENDIX F, APPENDIX G, 
APPENDIX H).  An official baseline overnight fasting blood draw (Week 0) was taken 
and subjects received the first incentive, a $10 Target gift card. During Week 4, 
participants returned for a midterm blood draw.  They received partial compensation, $15 
Target gift card, and questionnaires for Weeks 5-8.  One final travel to the Downtown 
Campus occurred at Week 8 to determine final blood values and provide the final portion 
of compensation of $20 Target gift card, which totaled to $45 in Target gift card. 
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Measurements 
Blood samples from all participants were taken at Weeks 0, 4, and 8.  Each 
subject fasted overnight for approximately 8 hours.  A Registered Nurse collected the 
blood samples in lavender top vaccutainers.  Vitamin C was analyzed calorimetrically 
(APPENDIX F) (Omaye, 1987).  Histamine was analyzed by ELISA assay (APPENDIX 
G) (ALPCO, 2013). 
 Additionally, questionnaires related to cold symptoms were completed by the 
subjects.  The Wisconsin Upper Respiratory Symptom Survey-21 was specifically used 
(Walter, 2008).  These questionnaires helped to examine symptoms experienced during 
the day as well as any medication use or exercise done throughout the day (APPENDIX 
D).  An asthma symptom survey was also recorded daily.  Weekly, a physical activity 
questionnaire and a vitamin C-focused FFQ were answered by the subjects. 
Questionnaires were scored according to the subjects’ answers.  
Statistical Analysis 
 Data was represented as mean ± SD.  All data was analyzed using SPSS 20 
system (Chicago, IL).  Originally, normality testing was planned be done, with potential 
transformation of data to reflect a normally distributed sample.  Once normality was 
established, an independent t-test was planned to be calculated.  However, the low 
number of subjects indicated for nonparametric testing.  Therefore, nonparametric 
independent samples test, Mann-Whitney U, was run to analyze data.  A p-value less than 
0.05 was considered statistically significant.    
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CHAPTER 4: DATA & RESULTS 
 Subjects were recruited for the study beginning of January 2014 until the end of 
March 2014.  A total of 76 interested participants completed the SurveyMonkey 
questionnaire.  Of those interested, approximately 50 qualified and were contacted via 
email for a screening date.  12 individuals set an appointment to meet with a researcher in 
ABC1 of the Downtown Phoenix campus.  Of those candidates, only nine subjects 
attended their appointments and were enrolled.  The nine subjects were stratified by 
gender, age, BMI, height, weight, body fat percentage, and screening plasma vitamin C 
into either the vitamin C treatment group or the control/placebo group.  Two subjects 
voluntarily dropped from the study between the Week 0 and Week 4; one participant 
discovered she was pregnant and the other participant ceased contact with the researchers 
for the follow-up appointments. Thus, the results encompass full assessments of the data 
from seven subjects, four in the vitamin C group (two males and two females) and 3 in 
the control group (one male and two females).  Compliance was adequate: 93.43%±7.2% 
for vitamin C and 87.5%±7.8% for control (FIGURE 1).  These should not impact the 
results. All data was analyzed through SPSS-22 (Chicago, IL), and normality was not 
tested due to the low subject number (n).  After discussion with lead researchers, the 
group concluded that utilizing nonparametric testing would be the  most appropriate 
method for analyzing the small data sample.  The non-parametric t-test, Mann Whitney 
U, was calculated for all comparisons.  
 Baseline data was similar for both groups.  Both groups were very similar in age 
(28.3± 9.9 years in vitamin C and 30.0± 9.6 years for the control group, p-value=1.000).  
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The groups were nearly identical in height, with 69.8±1.0 inches for vitamin C and 
68.8±7.6 inches for the control group.  There was a slight difference in weight 
(148.8±25.1 pounds in vitamin C and 164.6±45.0 pounds in control), BMI (21.5±3.4 
kg/m
2
 in vitamin C and 24.3±4.7 kg/m
2 
in control), and body fat percentage (20.8±12.1% 
in vitamin C and 25.8±12.2% in control).  However, none of these differences were large 
enough to be statistically significant (p-value was greater than 0.05).  Initial vitamin C 
intake and physical activity patterns were similar for both groups.  Yet, the large standard 
deviations indicate possible outliers.  With such a small sample, the outliers could not be 
removed.  Finally, the plasma vitamin C levels taken at the initial screen were below the 
recommended limits for the adult population (0.430±.257 mg/dL in vitamin C and 
0.585±.085 mg/dL in control, p-value = 0.480).  Overall, the stratification of subjects was 
appropriate, with no statistically significant difference in the major anthropometric and 
biochemical data. 
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Table 3 
Subject Data 
Table 3: Subject Data
a
 
 Vitamin C (n=4) Control Group (n=3) p-value
b
 
Gender 2 Female, 2 Male 2 Female, 1 Male --- 
Age (y) 28.3± 9.9 30.0± 9.6 1.000 
Height (in) 69.8±1.0 68.8±7.6 0.480 
Weight (lb) 148.8±25.1 164.6±45.0 0.480 
BMI (kg/m
2
) 21.5±3.4 24.3±4.7 0.480 
Body Fat (%) 20.8±12.1 25.8±12.2 0.480 
Initial Vitamin C 
(mg/dL) 
0.430±.257 0.585±.085 0.480 
Initial FFQ Scores 138.2±64.7 99.0±17.4 0.480 
Initial Physical 
Activity Scores 
30.3±19.4 68.3±64.9 0.480 
Pill Compliance 93.43±7.2 87.5±7.8 0.275
c
 
a
Values are mean ± SD  
b
Analysis by nonparametric independent samples test (Mann-Whitney U) 
c
Subject 9 (Vitamin C group) did not fill out the calendar to indicate compliance 
 
 Both groups started out with low vitamin C blood levels (0.512±0.217 mg/dL for 
vitamin C and 0.596±0.109 mg/dL for control).  The highest values in vitamin C occurred 
during Week 4 for vitamin C (0.922±0.190 mg/dL) and during Week 8 for control 
(0.745±0.123 mg/dL). The most noticeable change occurred between Week 0 and Week 
4 (0.410±0.041 mg/dL vitamin C and 0.122±0.082 mg/dL control).  This difference was 
not statistically significant (p=0.057). There was a larger change in vitamin C levels from 
Week 0 to Week 8 (0.283±0.110 mg/dL for vitamin C and 0.149±0.021 mg/dL for 
control).  However, this difference is not statistically significant (p=0.077).  The control 
group had a lower initial histamine level (0.858±1.103 ng/mL versus 1.818±0.909 ng/mL 
for vitamin C).  However, the difference is not statistically significant (p=0.229).  
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Overall, the vitamin C group decreased in histamine level throughout the eight weeks (-
0.344±1.270 ng/mL) while the control group had an increase in histamine level 
(0.451±1.162 ng/mL) but the difference was not statistically significant (p=0.724).  
Again, large standard deviations indicate a potential outlier, but the small n prevents the 
data from being thrown out. 
Table 4 
Blood Data 
Table 4: Blood Data
a
 
 Vitamin C (n=4) Control (n=3) p-value
b 
Vitamin C Week 0 (mg/dL) 0.512±0.217 0.596±0.109 0.857 
Vitamin C Week 4 (mg/dL) 0.922±0.190 0.718±0.089 0.114 
Vitamin C Week 8 (mg/dL) 0.795±0.276 0.745±0.123 0.629 
Vitamin C Mid-Change 
(Week 4 – Week 0) (mg/dL) 
0.410±0.041 0.122±0.082 0.057 
Vitamin C Change 
 (Week 8 – Week 0) 
(mg/dL) 
0.283±0.110 0.149±0.021 0.077 
Histamine Week 0 (ng/mL) 1.818±0.909 0.858±1.103 0.229 
Histamine Week 4 (ng/mL) 1.280±1.010 0.680±0.142 0.629
 
Histamine Week 8 (ng/mL) 1.474±1.693 1.309±0.216 0.400
 
Histamine Mid-Change 
(Week 4 – Week 0) (ng/mL) 
-0.538±1.740 -0.178±0.970 1.000 
Histamine Change  
(Week 8 – Week 0) (ng/mL) 
-0.344±1.270 0.451±1.162 0.724 
a
Values reported as mean ± SD 
b
Analysis by nonparametric independent samples test (Mann-Whitney U) 
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Figure 1. Comparison of pill compliance among subjects. 
 
Figure 2.  Graph of changes in blood histamine levels. 
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Figure 3. Graph of changes in blood vitamin C levels. 
There were noticeable differences between the groups regarding the cold 
symptoms recorded by the WURSS-21 questionnaires.  Overall, the vitamin C group 
seemed to have a lower recorded number of symptoms than the control group 
(129.25±120.7 versus 271.00±293.9) but the difference is not statistically significant 
(p=0.724).  The cold symptoms appeared to have affected the daily living of the control 
group slightly more than the vitamin C group but the difference is not significant 
(p=0.157).  The vitamin C group experienced cold symptoms from days 4-12 and then 
did not seem to have significant cold symptoms.  On the other hand, the control group 
experienced high cold symptoms day 16-36, according to FIGURE 4.  The colds had a 
slightly lesser effect on the living scores, but the length of colds are still reflected in 
FIGURE 4.  The differences are not statistically significant.  Due to the small population, 
each subject is graphed independently.   
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Table 5 
WURSS-21 Data 
Table 5: WURSS-21 Data
a 
over 8 weeks 
 Vitamin C (n=4) Control (n=3) p-value
b 
Total Symptoms 129.3±120.7 271.0±293.9 0.724 
Total Living 114.0±219.4 184.7±245.9 0.157 
a
Values reported as mean ± SD 
b
Analysis by nonparametric independent samples test (Mann-Whitney U) 
 
 
Figure 4. Total WURSS-21 scores throughout eight weeks.  
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Figure 5. WURSS-21 cold symptoms section scores. 
 
Figure 6. WURSS-21 daily living section scores.  
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Asthma symptoms were tracked by a daily asthma questionnaire.  Again, 
differences are only noticeable and not statistically significant (p>0.05). The vitamin C 
group had a slightly lower average asthma score (2.2±2.8) than the control group 
(5.0±2.4), but not a significant difference (p=0.154).  At the end of the eight weeks, the 
vitamin C group recorded a total of 17.8±22.5 while the control group recorded 
40.3±18.8 (p=0.154).  The vitamin C group appeared to have stable asthma scores 
throughout the study while the control group had more variation as seen in FIGURE 7. 
Subjects 2 and 9 have no recorded asthma symptoms during the eight weeks of vitamin C 
supplementation. 
Table 6 
Asthma Symptom Data 
Table 6: Asthma Symptoms Data
a
 
 Vitamin C (n=4) Control (n=3) p-value
b
 
Average Asthma 
Score 
2.2±2.8 5.0±2.4 0.154 
Total Asthma Score 17.8±22.5 40.3±18.8 0.154 
a
Values reported as mean ± SD 
b
Analysis by nonparametric independent samples test (Mann-Whitney U) 
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Figure 7. Asthma scores throughout eight weeks. 
 
Figure 8.Average and total asthma scores of the eight weeks.  
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Physical activity was monitored throughout the study, as shown in FIGURE 9.  
The control group appeared to be more physically active throughout the study than the 
vitamin C group.  The vitamin C group appeared to have more consistency in physical 
activity throughout the eight weeks than the control group.  The physical activity did not 
seem to impact the blood data. 
 
Figure 9. Trend of physical activity patterns of subjects. 
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Vitamin C consumed was monitored through a weekly FFQ.  Overall, most 
subjects appeared to be fairly stable with vitamin C intake.  One subject had very high 
intake compared to the other subjects.  However, the subject’s blood vitamin C level was 
not reflective of this increased intake.
 
Figure 10. Individual subjects’ vitamin C intake. 
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CHAPTER 5: DISCUSSION 
 With the current results of this double-blind, randomized controlled trial, there is 
not enough evidence to support the hypotheses.  In concurrence with the Cochrane 
review, the study conducted did not have enough subjects to strongly confirm or reject 
that vitamin C supplementation decreases cold symptoms or asthma symptoms in 
asthmatic adults (Milan, 2013).  The majority of studies from the Cochrane review have 
medium to low strength level; this study, at the current point, would be classified as low 
strength.  The study design called for at least 30 asthmatic individuals to reach a power of 
0.9. However, major issues with recruiting and maintaining contact with interested 
respondents contributed to the low subject outcome.    These low numbers prevented the 
researchers from seeing a clear trend, as evidenced by the p-values as well as the 
individual graphic representation.  This study’s current power does not reflect current 
evidence.  Vitamin C supplementation has been shown to significantly decrease 
bronchoconstriction in asthmatics post-exercise (Tecklenburg, 2007).  Another study 
found little to no effect from vitamin C in asthmatics and severity of bronchoconstriction; 
however, this study was also limited in small sample size (Nadi, 2012).  In colds, vitamin 
C research is vastly dependent on the subject population (Hemila, 2013). As reflected 
with this study, the role of vitamin C supplementation in asthmatics and the common cold 
are still unconfirmed.  A higher power of study is necessary to accept or reject the 
hypotheses. 
 Previous research has shown mixed results for vitamin C as a complementary 
treatment for asthma.  Studies have consistently shown that asthmatics have lower levels 
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of plasma vitamin C than their non-asthmatic counterparts (Allen, 2009).  However, 
supplementation may not always increase plasma vitamin C.  Children may see as much 
as a 50% decrease in plasma vitamin C during asthma episodes; this is thought to be 
attributed to an increased utilization of vitamin C to negate free radical behavior 
(Shanmugasundaram, 2001).  Researchers have shown a connection between the lower 
plasma vitamin C level and wheezing (Forastiere, 2000).  Lower vitamin C status is 
associated with decreased lung function, leading to episodes of wheezing (Forastiere, 
2000). Yet, even if the plasma vitamin C increases, some studies have found no change in 
spirometer measurements of respiratory activity (Nadi, 2012).   
Overall, the studies of vitamin C’s effectiveness against asthma have resulted in 
inconsistent answers (Riccioni, 2006).  Many studies have shown a negative relationship 
between vitamin C status and asthmatic episodes.  Those with a low vitamin C level have 
a 12% increased chance of having an asthma attack (Allen, 2009).  One study found that 
the intensity of asthma symptoms decreased after following a 1500mg vitamin C daily 
diet for two weeks (Tecklenburg, 2007).  Another study has found that 1000mg/day 
vitamin C supplementation for 16 weeks have no clinical benefits over standard medical 
therapy (Riccioni, 2006 and Milan, 2013).   
One major aspect of vitamin C’s action as a potential complementary therapy in 
asthmatics depends on the state of asthma.  Studies that have shown no clinical benefit 
are typically in adults with well-established asthma (Fogarty, 2003 and Allan, 2011).  In 
this study, all participants had asthma for at least 7 years.  Thus, this population may not 
see a strong benefit to vitamin C supplementation.  Although the study showed that the 
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vitamin C group had more control over their asthma symptoms over the eight weeks, a 
baseline asthma score was not taken.     
Another aspect of vitamin C’s effectiveness in protecting against asthma 
symptoms is the source of the asthma attack.  Vitamin C has proven to be effective 
against attacks generating from the environment and air pollutants (Riccioni, 2006 and 
Nadi, 2012).  These attacks are related to increase ROS production in the body from the 
multitude of particles in the air, and vitamin C has been shown to be effective in 
neutralizing ROS (Riccioni, 2006).  As this study occurred in central Phoenix alone, there 
was no difference in asthma attacks among the subjects.  Each subject has been an 
Arizona resident for at least two years and is likely adjusted to the pollution levels of this 
city.  Additionally, vitamin C would have no effect on LT-induced inflammatory 
response in the airway.  Vitamin C can decrease histamine levels, but cannot decrease LT 
levels (Liu, 2015). Overall, this study was not adequately powered and cannot reliably 
contribute to the discussion on vitamin C and asthma link.   
One important observation of this study relates to the blood data trends.  In both 
groups, serum vitamin C levels increased from baseline to week 4, but had a slight 
decrease in the treatment group.  This pattern is also reflected with the histamine blood 
data: a decrease from baseline to Week 4, but an increase from Week 4 to Week 8.  This 
is consistent with the inverse relationship established in other research (Gropper, 2013).  
Self-reported subject intake of vitamin C was fairly consistent, except for one participant.  
Additionally, physical activity does not seem to have played a part in the odd trend in 
blood data.  The vitamin C group had consistent physical activity patterns while the 
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control group had a greater variety.  The overall compliance rate was very high, and the 
dates of missed pills varied between subjects.  The difference between Week 4 and Week 
8 may indicate the study may be successful at only 4 weeks in length.  The decrease in 
length would assist in increasing subject compliance and participation, as length of study 
can defer some participants.  However, the 8-week long study has shown  promise in 
previous studies in both asthma (Nadi, 2012) and colds (Johnston, 2014).  No specific 
timeline for vitamin C research in the asthmatic population is evident; current studies 
range from two weeks to six months in length (Milan, 2013).   
 The WURSS-21 was utilized to measure any incidence of colds throughout the 
study.  During the eight weeks, only two participants, one in the control group and one in 
the vitamin C group, had a strong cold.  However, the low numbers prevent throwing out 
these “outliers”.  The symptoms section of the WURSS-21 was higher than the living 
section.  This could be representative of the asthmatic population as a whole.  The 
asthmatic individual is used to dealing with slightly obstructive airways.  Therefore, 
decreased breathing from stuffy or runny nose may not impact the asthmatic as much as a 
non-asthmatic individual.  Additionally, there may be overlap in symptoms from asthma 
and an upper respiratory airway infection, or cold.  These considerations may indicate 
that the WURSS-21 may not be appropriate for the asthmatic population.  However, it is 
still used in other asthma and common cold research (Busse, 1999 and Nadi, 2012).  One 
study has utilized the WURSS-21 in asthmatics to track the worsening of asthma 
symptoms following a cold (Walter, 2008).   
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 The asthma questionnaire results indicate the need for continuation of the study 
for vitamin C supplementation in asthmatics.  The subjects in the vitamin C 
supplementation group had consistent asthma symptoms compared to the control group, 
as evidenced in FIGURE 7, including the subject in the vitamin C group who had a 
severe cold. Although not statistically significant, the vitamin C group had lower asthma 
scores, comparatively.  This incidence requires a higher study population to support its 
importance. Previous studies have indicated that control over asthma symptoms decreases 
following an upper respiratory airway infection (Busse, 1999).  Other studies have shown 
that vitamin C supplementation can assist in stabilizing asthma symptoms (Milan, 2013).  
Studies have shown a potential protective factor of vitamin C in asthma, particularly in 
adults.  Asthma increases with oxidative stress, and vitamin C’s action as an antioxidant 
works to decrease the symptoms.  Although the population of this particular study was 
small, there is promise in showing a protective factor of 1000 mg vitamin C 
supplementation in adults.  Future studies are necessary. 
 Limitations and strengths. The major limitation with this study is the low 
subject turn-out.  The low subject population is consistent with the struggles in asthma 
studies (Cochrane).  No firm conclusion can be made from the data currently available.  
Only 25% of the goal participation was met in the year 2014.  For this study to contribute 
to the research in nutrition and asthma, the study should be repeated. using larger sample 
sizes and be conducted during the cold season.  .  Since the cold virus may change from 
year-to-year, the additional years of study would strengthen the validity of the study.   
Another limitation of the study is the subjective measure.  Although objective data is 
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taken at three different times in the study, the majority of the data is subjectively reported 
by the subjects themselves.  Especially among asthma, symptoms that may be severe to 
one participant may be mild to another.  More subjects participating in the study would 
help to balance out the subjectivity.  Utilizing other biomarkers of the asthmatic condition 
would have strengthened data interpretation, such as leukotriene B4.   
 While the success of this study is primarily hindered by the limitation, this study 
still has many strengths.  One strength was the high compliance rate.  Subjects consumed 
almost all the pills, and the lower compliance occurred in the placebo group.  
Additionally, the study is population-specific in an area in dire need of research data.  All 
subjects were diagnosed with asthma by a physician and provided a detailed medical 
history.  The methodology has been well-established for other populations with vitamin C 
and the common cold research studies.  This methodology is fairly appropriate for the 
asthmatic population.  Daily and weekly questionnaires and blood data allowed the 
researchers to analyze multiple aspects of vitamin C status and possible outside causes of 
increased inflammation.  Using questionnaires on a weekly basis allowed the participants 
to give a representation of their asthma, dietary, and physical activity patterns (Allen 
2009).  Additionally, using both biological data and questionnaires together to assess the 
interaction between the treatment and asthma status has been shown to be strong in 
previous studies (Allen 2009).  The classification of the study adds to its strength.  The 
third-party involvement of dividing the subjects into groups increased the validity of the 
study.   
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 Conclusion.  This study does not show a relationship between vitamin C and the 
asthmatic populations; however, the study was underpowered and the data cannot be 
adequately interpreted.  Future trials are needed given the importance of this topic and the 
fact that the currently literature is equivocal.     CAM treatments for the asthma are 
becoming more popular, particularly antioxidant supplementation coupling prescribed 
medications.  Vitamin C supplementation has been shown to help populations with 
abnormal ROS activity prevent colds.    More research is needed to establish its specific 
role in the asthmatic population. 
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APPENDIX A 
STUDY ADVERTISEMENT 
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Adults with Asthma Needed for ASU 
Asthma Trial  
The ASU Nutrition Program is recruiting adults with doctor-diagnosed 
asthma (18-65 years of age).  This 8-week trial will examine whether 
a dietary supplement may improve respiratory tract symptoms in 
asthmatics.  If you are willing to provide 4 blood samples and record 
respiratory tract symptoms daily for 8 weeks, you may be interested 
in this trial.  $45 in Target gift card will be awarded to participants at 
the end of the study. 
 
For more information or to apply for the study, please visit 
our recruitment site: 
https://www.surveymonkey.com/s/ASUAsthmaStudy 
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1. Select gender.  
1. Male  
2. Female 
2. Has your doctor diagnosed you with asthma? 
1. Yes  
2. No 
3. Do you currently smoke cigarettes? 
1. Yes  
2. No 
4. Do you take prescription medications every day to control your asthma? 
1. Yes  
2. No 
5. Do you use prescription medications (such as an inhaler) to treat your asthma 
symptoms when you have an asthma attack? 
1. Yes  
2. No 
6. Are you between 18 and 65 years old? 
1. Yes  
2. No 
7. Do you exercise vigorously over 4 times weekly and/or consider yourself a competitive 
athlete? 
1. Yes  
2. No 
3. Unsure 
8. Do you weigh at least 110 pounds? 
1. Yes  
2. No 
3. Unsure 
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9. Are you willing to have a small amount of blood taken from an arm vein (<1 
tablespoon) on 4 occasions during the trial? 
1. Yes  
2. No 
10. Are you currently being treated by a physician for a chronic disease or condition other 
than asthma (e.g.,  cancer, diabetes, arthritis, inflammatory bowel disease, heart disease, 
hepatitis, etc.)? 
1. Yes  
2. No 
11. Do you regularly take vitamin/mineral supplements? 
 If yes, please list. 
1. Yes  
2. No 
12. Are you willing to maintain your current diet pattern and activity level for 8 weeks? 
1. Yes  
2. No 
13. Are you willing to record respiratory tract symptoms daily for 8 weeks? 
1. Yes  
2. No 
14. Are you able to come to the ASU Downtown Phoenix Campus on 4 occasions in the 
next several month?  (The ASU nutrition laboratories are located at 5th Street and Van 
Buren.) 
1. Yes  
2. No 
3. Unsure 
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APPENDIX D 
CONSENT FORM 
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CONSENT FORM 
Impact of a Nutritional Supplement on Cold Symptoms in Asthmatics 
 
INTRODUCTION 
The purposes of this form are to provide you (as a prospective research study participant) information 
that may affect your decision as to whether or not to participate in this research and to record the 
consent of those who agree to be involved in the study. 
 
RESEARCHERS 
Dr. Carol Johnston, Associate Director and Professor, School of Nutrition and Health Promotion, and 
Kate Bratrud, a graduate student, have invited your participation in a research study that will last 8 
weeks.   
 
STUDY PURPOSE 
The purpose of this research is to evaluate the effect of a dietary supplement on cold and asthma 
symptoms. 
 
DESCRIPTION OF RESEARCH STUDY 
You have informed us that you have been diagnosed by a doctor with asthma and that you currently 
suffer from asthma.  If you decide to participate in this 8-week trial you will join a study examining the 
effect of a dietary supplement on respiratory tract symptoms.  You will be randomly assigned (by a coin 
toss) to receive either a nutritional supplement or a placebo. Neither you nor the researcher you are 
working with will know if you were assigned to the supplement group or the placebo group. You will 
be asked to take a capsule twice a day during the study and to keep a record of respiratory symptoms 
each day during the study.  You will be asked to not change your typical diet or physical activity 
patterns during the study and to not drink fruit/vegetable juice during the study.  The study involves 
four visits to the test site at the ASU Nutrition Labs on the Phoenix Downtown Campus (~15-20 
minutes each).  To measure nutrition markers, you will be asked to provide a fasting blood sample on 
three occasions.  A trained phlebotomist or registered nurse will draw all blood samples; each sample of 
blood is about 2 tablespoons.  You will be asked to complete a symptom questionnaire daily and 
physical activity and diet questionnaires weekly.  
 
If you say YES, then your participation will last about 8 weeks at the Arizona State University 
Downtown Phoenix Campus.  Approximately 40 subjects will be participating in this study. 
 
RISKS 
Potential risks of participating in this study involve general risks associated with giving a blood sample 
such as bruising or irritation at the site of venipuncture and faintness.  Ingestion of the dietary 
supplement may be associated with GI tract disturbances, which are usually alleviated when the 
supplement is ingested with food.  As with any research, there is some possibility that you may be 
subject to risks that have not yet been identified. 
 
BENEFITS  
Although there are no direct benefits to you, the possible benefits of your participation in the research 
are that you are contributing to scientific knowledge regarding the efficacy of a dietary supplement on 
symptoms of asthma. 
 
NEW INFORMATION 
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If the researchers find new information during the study that would reasonably change your decision 
about participating, then they will provide this information to you. 
 
CONFIDENTIALITY 
All information obtained in this study is strictly confidential unless disclosure is required by law. The 
results of this research study may be used in reports, presentations, and publications, but the researchers 
will not identify you.  In order to maintain confidentiality of your records, Dr. Carol Johnston will 
assign you a participant number.  Your name will not appear on any records aside from this consent 
form.  This form will be kept in Dr. Carol Johnston’s locked office to maintain your confidentiality.  
 
WITHDRAWAL PRIVILEGE 
It is OK for you to say no. Even if you say yes now, you are free to say no later, and withdraw from the 
study at any time.  Your decision will not affect your relationship with Arizona State University or 
otherwise cause a loss of benefits to which you might otherwise be entitled. 
 
COSTS AND PAYMENTS 
The researchers want your decision about participating in the study to be absolutely voluntary. Yet they 
recognize that your participation may pose some costs related to time and travel. Participants will 
receive a  gift card to Target at visits 2, 3, and 4 ($45 total).   
 
COMPENSATION FOR ILLNESS AND INJURY 
If you agree to participate in the study, then your consent does not waive any of your legal rights. 
However, no funds have been set aside to compensate you in the event of injury.  
        
VOLUNTARY CONSENT 
Any questions you have concerning the research study or your participation in the study, before or after 
your consent, will be answered by Carol Johnston, carol.johnston@asu.edu or (602)827-2265 and Kate 
Bratrud, kbratrud@asu.edu. 
  
If you have questions about your rights as a subject/participant in this research, or if you feel you have 
been placed at risk; you can contact the Chair of the Human Subjects Institutional Review Board, 
through the ASU Office of Research Integrity and Assurance, at 480-965 6788.  This form explains the 
nature, demands, benefits and any risk of the project.  By signing this form you agree knowingly to 
assume any risks involved.  Remember, your participation is voluntary.  You may choose not to 
participate or to withdraw your consent and discontinue participation at any time without penalty or loss 
of benefit.  In signing this consent form, you are not waiving any legal claims, rights, or remedies.  A 
copy of this consent form will be offered to you.   
 
Your signature below indicates that you consent to participate in the above study.   
 
 
________________________ _______________________  ___________________     
___________ 
Subject's Signature            Printed Name    Email                             Date 
 
INVESTIGATOR’S STATEMENT 
"I certify that I have explained to the above individual the nature and purpose, the potential benefits and 
possible risks associated with participation in this research study, have answered any questions that 
have been raised, and have witnessed the above signature. These elements of Informed Consent 
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conform to the Assurance given by Arizona State University to the Office for Human Research 
Protections to protect the rights of human subjects. I have provided (offered) the subject/participant a 
copy of this signed consent document." 
 
 
Signature of Investigator______________________________________     Date_____________ 
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              HEALTH HISTORY QUESTIONNAIRE                      
ID#___________________ 
                                                                            Height _________  Weight _______ 
1. Gender:  M    F 
 
2. Age:  __________ 
 
3. What year were you diagnosed by a physician for asthma?  ___________________ 
Have you experienced asthma-related symptoms in the recent months?  
 _____ Yes  _____  No 
Describe your asthma status:  
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
___ 
    
4. Ethnicity: (please circle one)  Native American    African-American   Caucasian    
Hispanic    Asian     Other 
 
5. Education (please circle):  HS diploma     Current college student       BS degree      MS 
degree       PhD degree 
 
6. Do you smoke?  _______  No, never    
                     _______  Yes   # Cigarettes per day = ________                               
                                 _______   I used to, but I quit ____ months ago [or ___years ago]  
 
7.  Do you take steroidal drugs for asthma (such as Symbicort, Advair, Flonase or Medrol) 
______ Yes    _____ No 
 
8.  Do you take any medications regularly?   _____  Yes  ____No           If yes, list type 
and frequency: 
Medication  month/year initiated                         Dosage             Frequency 
 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
9.  Do you currently take supplements (vitamins, minerals, herbs, etc.)?  ___Yes  ___No    
If yes, list type and frequency:                               
   to be completed by investigator 
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Supplement   month/year initiated                         Dosage             
Frequency 
 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
10.  Are you currently being treated by a physician for any condition other than asthma?   
____ Yes   ____  No  If yes, please elaborate 
_______________________________________________________________________ 
        
________________________________________________________________________ 
 
11.  How would you rate your lifestyle? 
Not active ______   Active ______    Somewhat active _______    Very Active________ 
 
 
12. During the previous 7-day period (one week), how many times on the average did 
you do the following kinds of exercise for more than 15 minutes during your free time? 
  
Light activities: 
(e.g., yoga, archery, fishing from river bank, bowling, horseshoes, golf, snow-
mobiling, easy walking) 
 Times per week:     0  1  2  3  4  5  6  7  8  9  10+ 
  
Moderate activities: 
(e.g., fast walking, baseball, tennis, easy bicycling, volleyball, badminton, 
easy swimming, alpine skiing, popular and folk dancing) 
 Times per week:     0  1  2  3  4  5  6  7  8  9  10+ 
  
Vigorous activities: 
(e.g., running, jogging, hockey, football, soccer, squash, basketball, cross 
country 
skiing, judo, roller skating, vigorous swimming, vigorous long distance 
bicycling) 
 Times per week:     0  1  2  3  4  5  6  7  8  9  10+ 
 
13. Do you consider yourself a competitive athlete?     _______ Yes    _______ No 
 
14.  How would you rate your lifestyle? 
Not active ___________      Active ___________ 
Somewhat active ________      Very Active ___________ 
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15.  Do you have any food allergies or restrictions?      Yes    No   If yes, explain: 
_______________________ 
 
16. How many times per week do you drink fruit or vegetable juice?   ___________ 
 
 
 
17. Circle how often you eat these foods (circle appropriate frequency): 
 
 Cruciferous vegetables   (broccoli, kale, Brussels sprouts, cauliflower, cabbage, collard greens, turnip greens, 
asparagus)                         
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-12x/yr……less 
 
 Melons  (cantaloupe, honeydew, watermelon, etc)                                                   
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-12x/yr……less 
 
 
 Citrus fruits   (oranges, grapefruit, lemons, etc)                                          
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-12x/yr……less 
 
 Citrus juices                                            
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-12x/yr……less 
 
 Strawberries                                            
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-12x/yr……less 
 
 Papaya, mangos, kiwi (including juices)   
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-12x/yr……less 
 
 Peppers  (sweet green, red, yellow, hot green chili, hot red chili, jalapeno)                                                 
 daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-12x/yr……less 
 
 Highly fortified breakfast cereals  (total, all bran, 100% bran, honey buckwheat crisp, bran buds, product 19, 
ovaltine, maypo, instant breakfast, etc)          
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-12x/yr……less 
 
 Fortified energy/fitness bars/drinks  (power bars, Powerade, etc)      
 daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-12x/yr……less 
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Day: Date: Time [To be completed at or near bedtime]: ID: 
Please fill in one circle for each of the following items:  
        Not  
   sick 
0 
 
Very                       Mild Moderate                                          Severe   
mild 
1 2 3 4 5 6 7 
In terms of respiratory tract illness               O 
only, how sick do you feel today?  
O O O O O O O 
 
Please rate the average severity of your cold symptoms over the last 24 hours for each symptom:  
Do not have  
this symptom 
0 
 
Very                       Mild Moderate                                          Severe   
mild 
1 2 3 4 5 6 7 
Runny nose O O O O O O O O 
Plugged nose O O O O O O O O 
Sneezing O O O O O O O O 
Sore throat O O O O O O O O 
Scratchy throat O O O O O O O O 
Cough O O O O O O O O 
Hoarseness O O O O O O O O 
Head congestion O O O O O O O O 
Chest congestion O O O O O O O O 
Feeling tired O O O O O O O O 
 
Over the last 24 hours, how much has your cold interfered with your ability to:  
Not  
at all 
0 
 
Very                       Mildly Moderately                             Severely 
mildly 
1 2 3 4 5 6 7 
Think clearly O O O O O O O O 
Sleep well O O O O O O O O 
Breathe easily O O O O O O O O 
Walk, climb stairs, exercise O O O O O O O O 
Accomplish daily activities O O O O O O O O 
Work outside the home O O O O O O O O 
Work inside the home O O O O O O O O 
Interact with others O O O O O O O O 
Live your personal life O O O O O O O O 
 
Compared to yesterday, I feel that my cold is:   [If you did not have cold symptoms yesterday, please leave blank.] 
Very much 
better 
Somewhat 
better 
A little  
better 
The same A little worse Somewhat 
worse 
Very much 
worse 
 O                         O                         O                        O                      O                       O                       O 
 
 
Please list any products (including prescription or over-the-counter medicines, herbal preparations or supplements,  
and/or lozenges) taken to relieve respiratory symptoms.   
Product 
name:   
 Dosage:   Time(s) taken:  
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Daytime Symptom Diary Scale questions 
1) How often did you experience asthma symptoms today? 
0  1  2  3  4  5  6 
None of      All of 
the time      the time 
 
2) How much did your asthma symptoms bother you 
today? 
0  1  2  3  4  5  6 
Not at all      Severely 
bothered      bothered 
 
3) How much activity could you do today? 
0  1  2  3  4  5  6 
More than      Less than 
usual activity      usual activity 
 
4) How often did your asthma affect your activities today? 
0  1  2  3  4  5  6 
None of      All of 
the time      the time 
 
Nocturnal Diary Scale question 
1) Did you wake up with asthma symptoms.  (This can be awakening in the middle of the night or 
on awakening in the morning)? 
❏ No ❏ Once ❏ More than once ❏ Awake "all night" 
 
Daytime Symptom Diary Scale and Nocturnal Diary Scale (developed by N.C. Santanello et al. 
92 
 
APPENDIX H 
FOOD FREQUENCY QUESTIONNAIRE 
 
 
  
93 
 
Circle how often you eat these foods (circle appropriate frequency): 
 
Cruciferous vegetables   (broccoli, kale, Brussels sprouts, cauliflower, cabbage, 
collard greens, turnip greens, asparagus)                         
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-
12x/yr……less 
 
Melons  (cantaloupe, honeydew, watermelon, etc)                                                   
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-
12x/yr……less 
 
 
Citrus fruits   (oranges, grapefruit, lemons, etc)                                          
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-
12x/yr……less 
 
Citrus juices                                            
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-
12x/yr……less 
 
Strawberries                                            
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-
12x/yr……less 
 
Papaya, mangos, kiwi (including juices)   
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-
12x/yr……less 
 
Peppers  (sweet green, red, yellow, hot green chili, hot red chili, jalapeno)                                                 
 daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-
12x/yr……less 
 
Highly fortified breakfast cereals  (total, all bran, 100% bran, honey buckwheat crisp, 
bran buds, product 19, ovaltine, maypo, instant breakfast, etc)          
daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-
12x/yr……less 
 
Fortified energy/fitness bars/drinks  (power bars, Powerade, etc)      
 daily…….3-6x/wk…….1-2x/wk…….3x/month……2x/month……1x/month…….6-
12x/yr……less 
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Collection, Assessment, and Calculations for Plasma Ascorbic Acid Assay  
(Omaye 1979) 
Solutions 
1. 5% TCA (Trichloroacetic Acid) 
 Weigh 5 g TCA, add up to 100 mL distilled H2O 
2. 10% TCA 
 Weigh 10 g TCA, add up to 100 mL distilled H2O 
3. 9N H2SO4 
 Measure 300 mL distilled H2O 
 Slowly add 100 mL 36N H2SO4 to the H2O 
4. 65% H2SO4 
 Measure 35 mL distilled H2O 
 Slowly add 65 mL 36N H2SO4 to the H2O 
5. DTC 
 Weigh 0.4 g Thirurea 
 Weigh 0.05 g CuSO4-5H2O 
 Weigh 3 g 2,4 dinitrophenyl hydrazine 
 Slowly add to 100 mL 9N H2SO4 
6. Stock Solution 
 Weigh 5 mg Ascorbate 
 Add to 25 mL 5% TCA 
 Separate into 1 mL aliquots and freeze at -43°C 
7. Working Solution 
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 Pipette 500 µL of Stock Solution and add to 5 mL 5% TCA, using graduated test 
tubes to measure 
Processing Steps: 
1. Draw blood into 7 mL EDTA tube.  Mix well and put on ice immediately.  Spin at 
2800 rpm for 10 minutes.   
2.Mix 2.5 mL plasma sample with 2.5 mL cold 10% TCA and vortex for 10 seconds. 
Spin immediately at 3500g for 20 minutes at 0°C.   
3.Aliquot supernatant into 3 aliquots at approximately 1.5 mL each.  Freeze immediately 
at -80°C. 
Standards Preparation: 
 
REAGENTS IN TUBE 
 
* CONCENTRATION 
Tube # μl Work Soln μl 5%TCA 
μl 
DTC 
 
μg 
AA/0.5ml 
AA 
mg/dl 
1 0 500 100 
 
0 0 
2 100 400 100 
 
2 0.4 
3 200 300 100 
 
4 0.8 
4 300 200 100 
 
6 1.2 
5 400 100 100 
 
8 1.6 
6 500 0 100 
 
10 2 
       SAMPLE 500 0 100 
 
sample sample 
 
Assay Procedure 
1. Prepare standards and samples as above. Incubate tubes for 3 hours at 37°C.  
2. Add 0.75mL (750 µL) ICE COLD 65% H2SO4 to all tubes.  Vortex for a count of 5 
seconds after each addition to mix. 
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3. Allow to stand at room temperature for approximately 30 minutes. Read at 520nm in 
spectrophotometer.  Use tube 1 as the blank. 
4. Using Excel, create a standard curve using Ascorbic Acid concentration (mg/dL) as x-
axis and absorbance as y-axis.  Produce a linear trend line and produce equation.  By 
solving for y = mx + b, Ascorbic Acid concentrations can be found. 
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HISTAMINE ASSAY 
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Histamine Elisa Assay Steps (ALPCO, 2013) 
1. Prepare Agents 
 Dilute the 20 mL Wash Buffer Concentrate with distilled water to a volume of 
1000 mL. 
 Keep the Acylation Diluent at room temperature to prevent freezing. 
 Each vial should be reconstituted with 1.25 mL Acylation Diluent. 
2. Sample preparation and acylation 
1. Pipette 25 μL of standards, 25 μL of controls, 25 μL of plasma samples, 10 μL of 
urine samples, or 50 μL of supernatant from the release test* into the respective wells 
of the Reaction Plate. 
2. Add 25 μL of Acylation Buffer to all wells. 
3. Add 25 μL of Acylation Reagent to all wells. 
4. Incubate for 45 min at RT (20-25°C) on a shaker (approx. 600 rpm). 
5. Add 200 μL of distilled water to all wells. 
6. Incubate for 15 min. at RT (20-25°C) on a shaker (approx. 600 rpm). Take 25 μL of 
the prepared standards, controls, and samples for the Histamine ELISA. 
3. Histamine ELISA 
1. Pipette 25 μL of the acylated standards, controls, and samples into the appropriate 
wells of the Histamine Microtiter Strips. 
2. Pipette 100 μL of the Histamine Antiserum into all wells and cover plate with 
Adhesive Foil. 
3. Incubate for 3 hours at RT (20-25°C) on a shaker (approx. 600 rpm). Alternatively: 
shake the Histamine Microtiter Strips briefly by hand and incubate for 15 – 20 hours at 
2 – 8°C. 
4. Remove the foil. Discard or aspirate the contents of the wells and wash each well 4 
times thoroughly with 300 μL Wash Buffer. Blot dry by tapping the inverted plate on 
absorbent material. 
5. Pipette 100 μL of the Enzyme Conjugate into all wells. 
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6. Incubate for 30 min at RT (20-25°C) on a shaker (approx. 600 rpm). 
7. Discard or aspirate the contents of the wells and wash each well 4 times thoroughly 
with 300 μL Wash Buffer. Blot dry by tapping the inverted plate on absorbent material. 
8. Pipette 100 μL of the Substrate into all wells and incubate for 20-30 min at RT (20-
25°C) on a shaker (approx. 600 rpm). Avoid exposure to direct sunlight! 
9. Add 100 μL of the Stop Solution to each well and shake the microtiter plate to ensure 
a homogeneous distribution of the solution. 
10. Read the absorbance of the solution in the wells within 10 minutes, using a 
microplate reader set to 450 nm with a reference wavelength between 620 nm and 650 
nm. 
4. Calculation of results 
 Concentration of the standards 
Standard A B C D E F 
Histamine  
(ng/mL = μg/L) 
0 0.5 1.5 5 15 50 
Histamine (nmol/L) 0 4.5 13.5 45 135 450 
Conversion: Histamine (ng/mL) x 9 = Histamine (nmol/L) 
The calibration curve is obtained by plotting the absorbance readings (calculate the mean 
absorbance) of the standards (linear, y-axis) against the corresponding standard 
concentrations (logarithmic, x-axis). Use a non-linear regression for curve fitting (e.g., 
spline, 4- parameter, akima). 
Plasma samples and controls: 
The concentrations of the plasma samples and the controls can be read directly from the 
standard curve. 
 
 
 
